<html lang="en" class="pb-page js" data-request-id="94d6eb9ff0710176-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6eb9ff0710176-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/fj2s5w7_vI4LtMqTQ4ARmEwUzHerNSWgN86xe4ashl5Gnt6PXqSvpBtjp6w7cT0NWjvnu2CBZN2WUVvOGP53yg=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6eb9ff0710176-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.3486205483146969"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="Specialties" content="Genetics|Neurology/Neurosurgery">
<meta name="topics" content="Neuromuscular Disease|Genetics General">
<meta name="articleCategory" content="Research"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2204705","title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","category":"Research","type":"Original Article","topics":"Neuromuscular Disease|Genetics General","specialties":"Genetics|Neurology/Neurosurgery","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-09-22T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Genetics|Neurology/Neurosurgery\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Neuromuscular Disease|Genetics General\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2204705","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Research Summary","title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","doi":"10.1056/NEJMdo006684","issueDate":"2022-09-22T00:00Z","age":"6Months-1990","isFree":"n","topics":"Neuromuscular Disease|Genetics General","viewType":"Full","specialties":"Genetics|Neurology/Neurosurgery"},{"type":"Quick Take","title":"Tofersen for SOD1 ALS","doi":"10.1056/NEJMdo006683","issueDate":"2022-09-22T00:00Z","age":"6Months-1990","isFree":"n","topics":"Neuromuscular Disease|Genetics General","viewType":"Full","specialties":"Genetics|Neurology/Neurosurgery"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6eb9ff0710176-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS"><meta name="dc.Creator" content="Timothy M. Miller"><meta name="dc.Creator" content="Merit E. Cudkowicz"><meta name="dc.Creator" content="Angela Genge"><meta name="dc.Creator" content="Pamela J. Shaw"><meta name="dc.Creator" content="Gen Sobue"><meta name="dc.Creator" content="Robert C. Bucelli"><meta name="dc.Creator" content="Adriano Chiò"><meta name="dc.Creator" content="Philip Van Damme"><meta name="dc.Creator" content="Albert C. Ludolph"><meta name="dc.Creator" content="Jonathan D. Glass"><meta name="dc.Creator" content="Jinsy A. Andrews"><meta name="dc.Creator" content="Suma Babu"><meta name="dc.Creator" content="Michael Benatar"><meta name="dc.Creator" content="Christopher J. McDermott"><meta name="dc.Creator" content="Thos Cochrane"><meta name="dc.Creator" content="Sowmya Chary"><meta name="dc.Creator" content="Sheena Chew"><meta name="dc.Creator" content="Han Zhu"><meta name="dc.Creator" content="Fan Wu"><meta name="dc.Creator" content="Ivan Nestorov"><meta name="dc.Creator" content="Danielle Graham"><meta name="dc.Creator" content="Peng Sun"><meta name="dc.Creator" content="Manjit McNeill"><meta name="dc.Creator" content="Laura Fanning"><meta name="dc.Creator" content="Toby A. Ferguson"><meta name="dc.Creator" content="Stephanie Fradette"><meta name="dc.Description" content="The intrathecally administered antisense oligonucleotide tofersen reduces synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with amyotrophic lateral sclerosis ..."><meta name="Description" content="The intrathecally administered antisense oligonucleotide tofersen reduces synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with amyotrophic lateral sclerosis ..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-09-22"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2204705"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202209223871208"><meta name="dc.Language" content="EN"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2204705">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2204705">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2204705">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS | NEJM">
        <meta property="og:title" content="Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2204705">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/2e979330-0135-497d-9176-2e81e9ab8249/nejmoa2204705_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/2e979330-0135-497d-9176-2e81e9ab8249/nejmoa2204705_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="The intrathecally administered antisense oligonucleotide tofersen reduces synthesis
of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with
amyotrophic lateral sclerosis ...">
        <meta name="twitter:description" content="The intrathecally administered antisense oligonucleotide tofersen reduces synthesis
of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with
amyotrophic lateral sclerosis ...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2204705">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2204705">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2022.387.issue-12;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;article:article:doi\:10.1056/NEJMoa2204705;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2204705" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2204705" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2204705" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2204705" class="inputDoi"><input type="hidden" value="T.M. Miller and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;387:1099-1110" class="inputCitation"><input type="hidden" value="09-21-2022" class="inputEPubDate"><input type="hidden" value="September 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6eb9ff0710176-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li><div style="clear: both;"></div></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Timothy M.</span> <span property="familyName">Miller</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Merit E.</span> <span property="familyName">Cudkowicz</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Angela</span> <span property="familyName">Genge</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Pamela J.</span> <span property="familyName">Shaw</span>, <span property="honorificSuffix">M.B., B.S., M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Gen</span> <span property="familyName">Sobue</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Robert C.</span> <span property="familyName">Bucelli</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Adriano</span> <span property="familyName">Chiò</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+19</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Philip</span> <span property="familyName">Van Damme</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Albert C.</span> <span property="familyName">Ludolph</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jonathan D.</span> <span property="familyName">Glass</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jinsy A.</span> <span property="familyName">Andrews</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Suma</span> <span property="familyName">Babu</span>, <span property="honorificSuffix">M.B., B.S., M.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Michael</span> <span property="familyName">Benatar</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-4241-5135" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-4241-5135</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Christopher J.</span> <span property="familyName">McDermott</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Thos</span> <span property="familyName">Cochrane</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sowmya</span> <span property="familyName">Chary</span>, <span property="honorificSuffix">M.B., B.S., M.M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sheena</span> <span property="familyName">Chew</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Han</span> <span property="familyName">Zhu</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Fan</span> <span property="familyName">Wu</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ivan</span> <span property="familyName">Nestorov</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Danielle</span> <span property="familyName">Graham</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Peng</span> <span property="familyName">Sun</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Manjit</span> <span property="familyName">McNeill</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Laura</span> <span property="familyName">Fanning</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Toby A.</span> <span property="familyName">Ferguson</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Stephanie</span> <span property="familyName">Fradette</span>, <span property="honorificSuffix">Pharm.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the VALOR and OLE Working Group<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-19</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">September 21, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">387</span></span>:<span property="pageStart">1099</span>-<span property="pageEnd">1110</span></div><div class="doi">DOI: 10.1056/NEJMoa2204705</div><div class="core-enumeration"><a href="/toc/nejm/387/12"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">387</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">12</span></span></a></div><div><a href="#tab-information">Copyright © 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DTimothy%2BM.%2BMiller%252C%2BMerit%2BE.%2BCudkowicz%252C%2BAngela%2BGenge%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D12%26contentID%3D10.1056%252FNEJMoa2204705%26title%3DTrial%2Bof%2BAntisense%2BOligonucleotide%2BTofersen%2Bfor%2B%253Ci%253ESOD1%253C%252Fi%253E%2BALS%26publicationDate%3D09%252F22%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2204705" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DTimothy%2BM.%2BMiller%252C%2BMerit%2BE.%2BCudkowicz%252C%2BAngela%2BGenge%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D12%26contentID%3D10.1056%252FNEJMoa2204705%26title%3DTrial%2Bof%2BAntisense%2BOligonucleotide%2BTofersen%2Bfor%2B%253Ci%253ESOD1%253C%252Fi%253E%2BALS%26publicationDate%3D09%252F22%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/80c1ee7d-d743-41b8-8ec5-fd9508aa25ea/nejmoa2204705.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2204705.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2204705" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2204705" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2204705.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">The intrathecally administered antisense oligonucleotide tofersen reduces synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with amyotrophic lateral sclerosis (ALS) associated with mutations in <i>SOD1</i> (<i>SOD1</i> ALS).</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In this phase 3 trial, we randomly assigned adults with <i>SOD1</i> ALS in a 2:1 ratio to receive eight doses of tofersen (100 mg) or placebo over a period of 24 weeks. The primary end point was the change from baseline to week 28 in the total score on the ALS Functional Rating Scale–Revised (ALSFRS-R; range, 0 to 48, with higher scores indicating better function) among participants predicted to have faster-progressing disease. Secondary end points included changes in the total concentration of SOD1 protein in cerebrospinal fluid (CSF), in the concentration of neurofilament light chains in plasma, in slow vital capacity, and in handheld dynamometry in 16 muscles. A combined analysis of the randomized component of the trial and its open-label extension at 52 weeks compared the results in participants who started tofersen at trial entry (early-start cohort) with those in participants who switched from placebo to the drug at week 28 (delayed-start cohort).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204705_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204705_f0.jpg"><img src="/cms/10.1056/NEJMoa2204705/asset/2e979330-0135-497d-9176-2e81e9ab8249/assets/images/large/nejmoa2204705_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 72 participants received tofersen (39 predicted to have faster progression), and 36 received placebo (21 predicted to have faster progression). Tofersen led to greater reductions in concentrations of SOD1 in CSF and of neurofilament light chains in plasma than placebo. In the faster-progression subgroup (primary analysis), the change to week 28 in the ALSFRS-R score was −6.98 with tofersen and −8.14 with placebo (difference, 1.2 points; 95% confidence interval [CI], −3.2 to 5.5; P=0.97). Results for secondary clinical end points did not differ significantly between the two groups. A total of 95 participants (88%) entered the open-label extension. At 52 weeks, the change in the ALSFRS-R score was −6.0 in the early-start cohort and −9.5 in the delayed-start cohort (difference, 3.5 points; 95% CI, 0.4 to 6.7); non–multiplicity-adjusted differences favoring early-start tofersen were seen for other end points. Lumbar puncture–related adverse events were common. Neurologic serious adverse events occurred in 7% of tofersen recipients.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In persons with <i>SOD1</i> ALS, tofersen reduced concentrations of SOD1 in CSF and of neurofilament light chains in plasma over 28 weeks but did not improve clinical end points and was associated with adverse events. The potential effects of earlier as compared with delayed initiation of tofersen are being further evaluated in the extension phase. (Funded by Biogen; VALOR and OLE ClinicalTrials.gov numbers, <a href="http://clinicaltrials.gov/show/NCT02623699" target="_blank">NCT02623699</a> and <a href="http://clinicaltrials.gov/show/NCT03070119" target="_blank">NCT03070119</a>; EudraCT numbers, <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004098-33" target="_blank">2015-004098-33</a> and <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003225-41" target="_blank">2016-003225-41</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006683/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/9b02b884-42c7-4931-ab3c-e8f07d2353bf/media/NEJMdo006683_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006683/full/" class="ng-do-media_item-title-link">Tofersen for <i>SOD1</i> ALS</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 18s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Approximately 2% of cases of amyotrophic lateral sclerosis (ALS) are associated with mutations in the gene encoding superoxide dismutase 1 (<i>SOD1</i>).<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2" href-manipulated="true">1,2</a></sup> More than 200 ALS-associated <i>SOD1</i> mutations have been described and are associated with variable rates of progression.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4 r5 r6 r7" id="body-ref-r7" href-manipulated="true">3-7</a></sup> Neuronal degeneration in this disorder is considered to be caused by toxic gain of function of the mutant SOD1 protein.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r8 r9 r10 r11 r12" id="body-ref-r12" href-manipulated="true">1,8–12</a></sup> Tofersen is an intrathecally administered antisense oligonucleotide designed to reduce the synthesis of SOD1 protein by inducing RNase H–mediated degradation of <i>SOD1</i> messenger RNA.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r13 r14 r15" id="body-ref-r15-1" href-manipulated="true">10,13–15</a></sup> We conducted a 28-week, phase 3, randomized trial of the efficacy and safety of tofersen in adults with <i>SOD1</i> ALS. This is part C (VALOR) of a three-part trial, the first two parts of which were dose-escalation trials conducted to assess the dose of tofersen to be used in part C (see the <a href="#ap1">protocol</a>, available with the full text of this article at NEJM.org).<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15-2" href-manipulated="true" aria-label="Reference 15">15</a></sup> Participants who were enrolled in parts A and B were not enrolled in part C. After completion of this trial, participants had the opportunity to enroll in an ongoing open-label extension.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Oversight</h3><div role="paragraph">The trials were conducted in accordance with the Good Clinical Practice guidelines of the International Council for Harmonisation and the ethical principles outlined in the Declaration of Helsinki. The protocols of VALOR and its open-label extension were approved by relevant ethics committees. An independent data monitoring committee reviewed safety data. Written informed consent for both the randomized phase and open-label extension was provided by participants or their legal representatives.</div><div role="paragraph">The sponsor, Biogen, and the authors designed these trials. Biogen provided tofersen and placebo, oversaw the trial, performed the statistical analyses, and paid for medical writing assistance. Biogen and the authors analyzed the data. The first draft of the manuscript was written by the first author and an author employed by Biogen. The sponsor reviewed the manuscript but could not delay or prevent publication of the results. The authors reviewed and approved revisions of the manuscript and vouch for the accuracy and completeness of the data, the fidelity of the trials to the protocols, and the accuracy of the reporting of adverse events. There were confidentiality agreements between the authors and Biogen.</div></section><section id="sec-1-2"><h3>Trial Design</h3><div role="paragraph">The phase 3, double-blind, randomized, placebo-controlled VALOR component of the trial was conducted from March 2019 through July 2021.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16-1" href-manipulated="true" aria-label="Reference 16">16</a></sup> Participants were enrolled at 32 sites in 10 countries (see Section S1 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org). The trial included a 4-week screening period, a 24-week treatment period, and a follow-up period of 4 to 8 weeks followed by an ongoing extension phase.</div><div role="paragraph">Participants were randomly assigned in a 2:1 ratio to receive an intrathecal bolus injection through a lumbar puncture of a 15-ml solution of tofersen (100 mg) or an equivalent volume of placebo (artificial cerebrospinal fluid [CSF]) administered over a period of 24 weeks, as three doses once every 2 weeks, followed by five doses once every 4 weeks (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>). Randomization was stratified according to the use or nonuse of edaravone, riluzole, or both at baseline and according to whether participants met prognostic criteria for faster disease progression that were based on <i>SOD1</i> mutation type and the estimated slope of the score on the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R), calculated from the time of symptom onset until screening (“prerandomization ALSFRS-R slope”). Owing to the potential for nonlinear progression on the ALSFRS-R score and for intra-mutation variability confounding the prognostic value of these measures, as well as literature supporting the use of neurofilament light chains as a prognostic marker of disease progression,<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16 r17 r18 r19 r20 r21 r22 r23 r24" id="body-ref-r24" href-manipulated="true">16-24</a></sup> analyses in subgroups that were defined according to baseline concentrations of neurofilament light chains in plasma (above vs. below the median concentration for the trial population) were prespecified before VALOR results were available (see Section S2 in the <a href="#ap2">Supplementary Appendix</a>).</div><div role="paragraph">After completion of VALOR, participants were given the option to participate in an open-label extension for up to 236 weeks, while remaining unaware of their trial-group assignment in VALOR. The combined analysis at week 52 of VALOR and its open-label extension was prespecified and was intended to enable comparison of early-start and delayed-start tofersen in the full intention-to-treat population. The extension phase is ongoing, and analysis is planned when all participants have completed at least 3.5 years of follow-up, which has not been reached.</div></section><section id="sec-1-3"><h3>Participants</h3><div role="paragraph">We enrolled adults with weakness attributable to ALS and a confirmed <i>SOD1</i> mutation. The primary analysis population was the subgroup of participants who met the trial-defined prognostic criteria for faster-progressing disease (see Section S2 in the <a href="#ap2">Supplementary Appendix</a>) and is called the “faster-progression subgroup.” Also undergoing randomization was a subgroup of participants who did not meet these enrichment criteria and were predicted to have slower progression of disease, the slower-progression subgroup. These persons were not included in the primary end-point analysis but had the opportunity to enroll in the open-label extension to receive tofersen. In the evaluation of combined data from VALOR and its open-label extension, participants who initiated tofersen in VALOR are referred to as the “early-start cohort,” regardless of whether they were predicted to have faster-progressing or slower-progressing disease in the randomized part of the trial. Those who received placebo in VALOR and had the opportunity to cross over to tofersen in the open-label extension approximately 28 weeks later are referred to as the “delayed-start cohort.”</div></section><section id="sec-1-4"><h3>End Points</h3><div role="paragraph">The primary efficacy end point in VALOR was the change from baseline to week 28 in the ALSFRS-R total score in the faster-progression subgroup. The ALSFRS-R consists of 12 items across four subdomains of function (bulbar, fine motor, gross motor, and breathing), with total scores ranging from 0 to 48 and higher scores indicating better function. Prespecified secondary end points included the change from baseline in the total concentration of SOD1 protein in CSF, the concentration of neurofilament light chains in plasma, the percentage of the predicted slow vital capacity (volumes were standardized to the percentage of the predicted normal value on the basis of age, sex, and height), the handheld dynamometry megascore (average of z-scores across 16 muscle groups in the arms and legs, with higher values indicating greater strength), the time to death or permanent ventilation (≥22 hours of mechanical ventilation per day for ≥21 consecutive days), the time to death, and safety. Prespecified exploratory end points included participant-reported outcome measures such as the five-item Amyotrophic Lateral Sclerosis Assessment Questionnaire, fatigue (Fatigue Severity Scale), and quality of life (EuroQol Group 5-Dimension questionnaire). The same end points were assessed as part of the combined analyses of VALOR and the open-label extension.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">We calculated that a sample size of 60 participants (2:1 randomization ratio) in the faster-progression primary analysis subgroup would provide 84% power to detect a between-group difference on the basis of the joint rank test (described below), assuming a change in the ALSFRS-R score from baseline to week 28 of −4.8 in the tofersen group and −24.7 in the placebo group, with a standard deviation of 20.39 and survival of 90% in the tofersen group and 82% in the placebo group, at a two-sided alpha level of 0.05. All primary and secondary end points for the 28-week randomized part of the trial were formally tested in the faster-progression subgroup. In the slower-progression subgroup, only the total SOD1 concentration in CSF was powered to test for statistical significance and was the primary end point in this population (Table S3). The joint rank test was used for statistical inference in the analysis of the change in the ALSFRS-R score. This accounts for both functional decline and survival and allows for a statistical test of the treatment effect while accounting for truncation of data owing to deaths. The joint rank score was calculated by comparing the change in each participant’s ALSFRS-R score from baseline to week 28 with that of every other participant in the trial, resulting in a score of 1 if the outcome was better than that of the participant being compared, –1 if worse, and 0 if the same. Participants who died were ranked lowest on the basis of their time to death, with progressively lower ranks given to those who died in the shortest period of time after the first dose. The sum of individual scores for each participant (i.e., ranked score) was assessed with the use of analysis of covariance (ANCOVA).</div><div role="paragraph">The ANCOVA model for ranked scores on the ALSFRS-R included trial group as a fixed effect and was adjusted for covariates (baseline disease duration since symptom onset, baseline ALSFRS-R total score, and use of riluzole or edaravone). The estimated between-group difference was obtained from the ANCOVA model for change from baseline in the ALSFRS-R score. Formal statistical testing for the overall population of all randomly assigned participants (irrespective of faster or slower predicted progression) was not specified for VALOR, but estimates are provided from the ANCOVA for change from baseline. Joint rank analysis was performed in conjunction with multiple imputation to account for missing data due to withdrawals not accounted for by death. The multiple-imputation model included trial group, use of riluzole or edaravone, and the baseline ALSFRS-R score. Additional subgroup and exploratory end points and analyses are described in Sections S3 and S4 in the <a href="#ap2">Supplementary Appendix</a>.</div><div role="paragraph">If the results for the primary end point differed significantly between the two trial groups, secondary end points for the faster-progression subgroup were tested with the use of a sequential closed testing procedure in order of ranking: the change from baseline (ratio to baseline) to week 28 in the total concentration of SOD1 protein in CSF, the change from baseline (ratio to baseline) to week 28 in the concentration of neurofilament light chains in plasma, the change from baseline to week 28 in the percentage of the predicted slow vital capacity, the change from baseline to week 28 in handheld dynamometry megascore, ventilation assistance–free survival, and overall survival. ANCOVA for change from baseline was used for all continuous end points and in conjunction with multiple imputation for handling missing data for withdrawals. Primary statistical inference for slow vital capacity was by joint rank analysis with the use of multiple imputation. For survival analyses, data for participants who did not meet the end-point definition were censored at the end of the trial or on the date of withdrawal. Only events that were adjudicated by the independent end-point adjudication committee were included. Treatment effects were assessed at a two-sided significance level of 0.05.</div><div role="paragraph">The first data cutoff for the combined analysis of data from VALOR and its open-label extension to evaluate the effects of early as compared with delayed initiation of tofersen was performed in July 2021. A second data cutoff of the open-label extension was performed on January 16, 2022, when the last participant who underwent randomization in VALOR had the opportunity for at least 52 weeks of follow-up from the start of VALOR. The combined analyses of these data are presented here. At the time that data from the January 2022 data cutoff were analyzed, the final results from VALOR and the original analysis of VALOR and its open-label extension had been presented at a scientific congress; however, participants, investigators and site staff, and the trial team remained unaware during the extension phase of the original trial-group assignments in VALOR.</div><div role="paragraph">Prespecified analyses of the data from VALOR and the data as of the first data cutoff of the open-label extension were performed on the basis of enrichment criteria (fast-progression and slow-progression subgroups) and of categorical subgroups defined by the median concentration of neurofilament light chains in plasma at baseline. Recognizing that adjusting for a continuous variable as a covariate more precisely controls for individual heterogeneity than dichotomizing the population into categorical subgroups, we amended the statistical analysis plan before analysis of the January 2022 data cutoff to incorporate the baseline concentration of neurofilament light chains in plasma as a covariate across analyses (Sections S2 and S4 in the <a href="#ap2">Supplementary Appendix</a>).</div><div role="paragraph">The combined analyses of the data as the January 2022 data cutoff are based on the intention-to-treat principle, whereby all participants who underwent randomization in VALOR (108 participants) are included according to their original trial-group assignment, regardless of fast or slow progression, adherence to the trial agent, early termination of the trial, or crossover to the tofersen group. The ANCOVA analyses in conjunction with multiple imputation were conducted identically to the analyses in VALOR. Kaplan–Meier survival analyses included all data up to January 16, 2022, for time to death or permanent ventilation and time to death; between-group comparisons for these end points were based on a log-rank test stratified according to trial group and the median concentration of neurofilament light chains in plasma at baseline (Section S4 and Table S5 in the <a href="#ap2">Supplementary Appendix</a>). Because there was no plan for adjustment of the widths of confidence intervals for multiple comparisons in the combined analysis, no conclusions can be drawn from these results.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Participants</h3><div role="paragraph">A total of 108 participants with 42 unique <i>SOD1</i> mutations (Table S1) were enrolled in VALOR; 72 were assigned to receive tofersen and 36 to receive placebo. A total of 60 of the 108 participants made up the faster-progression subgroup in which the primary analysis was performed. A total of 95 VALOR participants (88%) were enrolled in the open-label extension (Fig. S3). The amount of missing data for the combined analysis is given below. The clinical characteristics of the participants at baseline were similar in the two trial groups for use of riluzole, edaravone, or both, time from onset of disease symptoms, baseline ALSFRS-R score, and percentage of predicted slow vital capacity. However, baseline concentrations of neurofilament light chains were 15 to 25% higher in participants who received tofersen than in those who received placebo, and the rate of decline in the ALSFRS-R score from screening to day 15 (a period of approximately 42 days) was greater in the participants who received tofersen (<a href="#t1">Table 1</a>). The mean ALSFRS-R score at baseline was approximately 37 in both groups.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204705_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204705_t1.jpg"><img src="/cms/10.1056/NEJMoa2204705/asset/b689ed23-3805-4fe6-8e60-c86f5bac03a0/assets/images/large/nejmoa2204705_t1.jpg" height="2089" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="2"><span>Faster-Progression Subgroup (N=60)<a href="#t1fn2" role="doc-noteref">†</a></span></th><th class="txxx-borders" colspan="2"><span>Slower-Progression Subgroup (N=48)</span></th><th class="txxr-borders" colspan="2"><span>Overall (N=108)<a href="#t1fn3" role="doc-noteref">‡</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Placebo<br>(N=21)</th><th class="xxxx-borders">Tofersen<br>(N=39)</th><th class="xxxx-borders">Placebo<br>(N=15)</th><th class="xxxx-borders">Tofersen<br>(N=33)</th><th class="xxxx-borders">Placebo<br>(N=36)</th><th class="xxxr-borders">Tofersen<br>(N=72)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">54.0±12.2</td><td class="xxxx-borders shading">47.3±14.3</td><td class="xxxx-borders shading">47.3±9.8</td><td class="xxxx-borders shading">49.0±10.5</td><td class="xxxx-borders shading">51.2±11.6</td><td class="xxxr-borders shading">48.1±12.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders">11 (52)</td><td class="xxxx-borders">22 (56)</td><td class="xxxx-borders">8 (53)</td><td class="xxxx-borders">21 (64)</td><td class="xxxx-borders">19 (53)</td><td class="xxxr-borders">43 (60)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Body-mass index<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">28.0±6.2</td><td class="xxxx-borders shading">26.7±6.4</td><td class="xxxx-borders shading">26.6±7.0</td><td class="xxxx-borders shading">26.2±4.6</td><td class="xxxx-borders shading">27.4±6.5</td><td class="xxxr-borders shading">26.4±5.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Riluzole use — no. (%)</td><td class="xxxx-borders">13 (62)</td><td class="xxxx-borders">25 (64)</td><td class="xxxx-borders">9 (60)</td><td class="xxxx-borders">20 (61)</td><td class="xxxx-borders">22 (61)</td><td class="xxxr-borders">45 (62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Edaravone use — no. (%)</td><td class="xxxx-borders shading">1 (5)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">2 (13)</td><td class="xxxx-borders shading">4 (12)</td><td class="xxxx-borders shading">3 (8)</td><td class="xxxr-borders shading">6 (8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Time from symptom onset — min<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median (IQR)</td><td class="xxxx-borders shading">8.3 (5.1 to 12.1)</td><td class="xxxx-borders shading">8.3 (6.0 to 10.4)</td><td class="xxxx-borders shading">39.6 (30.3 to 53.6)</td><td class="xxxx-borders shading">35.5 (19.5 to 60.9)</td><td class="xxxx-borders shading">14.6 (6.6 to 32.0)</td><td class="xxxr-borders shading">11.4 (7.2 to 28.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Range</td><td class="xxxx-borders">2.4 to 21.3</td><td class="xxxx-borders">1.7 to 18.5</td><td class="xxxx-borders">11.8 to 103.2</td><td class="xxxx-borders">3.9 to 145.7</td><td class="xxxx-borders">2.4 to 103.2</td><td class="xxxr-borders">1.7 to 145.7</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Concentration of neurofilament light chains in plasma — pg/ml</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean</td><td class="xxxx-borders">127.3±94.4</td><td class="xxxx-borders">146.2±82.6</td><td class="xxxx-borders">37.0±29.5</td><td class="xxxx-borders">47.6±41.8</td><td class="xxxx-borders">89.7±86.5</td><td class="xxxr-borders">100.4±82.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Geometric mean</td><td class="xxxx-borders shading">92.7</td><td class="xxxx-borders shading">121.8</td><td class="xxxx-borders shading">28.4</td><td class="xxxx-borders shading">33.2</td><td class="xxxx-borders shading">56.6</td><td class="xxxr-borders shading">66.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Range</td><td class="xxxx-borders">9 to 370</td><td class="xxxx-borders">12 to 329</td><td class="xxxx-borders">8 to 99</td><td class="xxxx-borders">5 to 211</td><td class="xxxx-borders">8 to 370</td><td class="xxxr-borders">5 to 329</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ALSFRS-R prerandomization slope — points per mo<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean</td><td class="xxxx-borders">–1.81±1.17</td><td class="xxxx-borders">–1.74±1.58</td><td class="xxxx-borders">–0.26±0.25</td><td class="xxxx-borders">–0.30±0.20</td><td class="xxxx-borders">–1.16±1.19</td><td class="xxxr-borders">–1.08±1.37</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">–4.91 to –0.42</td><td class="xxxx-borders shading">–8.30 to –0.39</td><td class="xxxx-borders shading">–0.84 to –0.02</td><td class="xxxx-borders shading">–0.77 to 0.00</td><td class="xxxx-borders shading">–4.91 to –0.02</td><td class="xxxr-borders shading">–8.30 to 0.00</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">ALSFRS-R run-in slope — points per mo<a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean</td><td class="xxxx-borders shading">–1.3±3.9</td><td class="xxxx-borders shading">–1.8±2.5</td><td class="xxxx-borders shading">0.1±1.9</td><td class="xxxx-borders shading">–0.1±1.3</td><td class="xxxx-borders shading">–0.7±3.3</td><td class="xxxr-borders shading">–1.0±2.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Range</td><td class="xxxx-borders">–11 to 10</td><td class="xxxx-borders">–9 to 3</td><td class="xxxx-borders">–3 to 4</td><td class="xxxx-borders">–3 to 4</td><td class="xxxx-borders">–11 to 10</td><td class="xxxr-borders">–9 to 4</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ALSFRS-R total score</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean</td><td class="xxxx-borders">35.4±5.7</td><td class="xxxx-borders">36.0±6.4</td><td class="xxxx-borders">39.9±5.1</td><td class="xxxx-borders">38.1±5.1</td><td class="xxxx-borders">37.3±5.8</td><td class="xxxr-borders">36.9±5.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">24 to 45</td><td class="xxxx-borders shading">15 to 44</td><td class="xxxx-borders shading">32 to 47</td><td class="xxxx-borders shading">26 to 48</td><td class="xxxx-borders shading">24 to 47</td><td class="xxxr-borders shading">15 to 48</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Percentage of predicted slow vital capacity</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean</td><td class="xxxx-borders shading">83.7±17.9</td><td class="xxxx-borders shading">80.3±14.2</td><td class="xxxx-borders shading">87.1±14.8</td><td class="xxxx-borders shading">84.2±19.0</td><td class="xxxx-borders shading">85.1±16.5</td><td class="xxxr-borders shading">82.1±16.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Range</td><td class="xbxx-borders">57.4 to 120.4</td><td class="xbxx-borders">46.7 to 114.8</td><td class="xbxx-borders">54.8 to 114.4</td><td class="xbxx-borders">55.4 to 134.7</td><td class="xbxx-borders">54.8 to 120.4</td><td class="xbxr-borders">46.7 to 134.7</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Participants at Baseline (Intention-to-Treat Population).<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. Total scores on the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R) range from 0 to 48, with higher scores indicating better function. IQR denotes interquartile range.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">These participants were included in the randomized VALOR component of the trial.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">These participants were included in the combined analysis.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">The time since the onset of symptoms of amyotrophic lateral sclerosis (ALS) was calculated in months as (date of baseline minus date of ALS symptom onset) divided by 30.4375.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">The prerandomization ALSFRS-R slope was calculated as (maximum possible score of 48 minus ALSFRS-R score at baseline [day 1]) divided by time since symptom onset.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">The run-in ALSFRS-R slope reflects the rate of decline in the ALSFRS-R score from screening to day 15 (run-in period of approximately 42 days).</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>End Points</h3><section id="sec-2-2-1"><h4>Primary End Point in VALOR</h4><div role="paragraph">Among the 60 participants in the faster-progression primary analysis subgroup, the change in the ALSFRS-R total score from baseline to week 28 was –6.98 points in the tofersen group and –8.14 points in the placebo group (difference, 1.2 points; 95% confidence interval [CI], –3.2 to 5.5; P=0.97) (<a href="#t2">Table 2</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204705_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204705_t2.jpg"><img src="/cms/10.1056/NEJMoa2204705/asset/da490f89-2198-4f02-862c-445600baa7f5/assets/images/large/nejmoa2204705_t2.jpg" height="1865" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">Placebo<br>(N=21)</th><th class="txxr-borders">Tofersen<br>(N=39)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Primary end point</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">ALSFRS-R total score<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Adjusted mean change from VALOR baseline</td><td class="xxxx-borders shading">–8.14</td><td class="xxxr-borders shading">–6.98</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Adjusted mean difference: tofersen minus placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">1.2 (–3.2 to 5.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">P value according to joint rank test and multiple imputation</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">0.97</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Secondary end points</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Total SOD1 concentration in CSF</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjusted geometric mean ratio to VALOR baseline</td><td class="xxxx-borders">1.16</td><td class="xxxr-borders">0.71</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Geometric mean ratio: tofersen vs. placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">0.62 (0.49 to 0.78)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Concentration of neurofilament light chains in plasma</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Adjusted geometric mean ratio to VALOR baseline</td><td class="xxxx-borders shading">1.20</td><td class="xxxr-borders shading">0.40</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Geometric mean ratio: tofersen vs. placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">0.33 (0.25 to 0.45)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Percentage of predicted slow vital capacity — percentage points</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjusted mean change from VALOR baseline</td><td class="xxxx-borders">–22.20</td><td class="xxxr-borders">–14.31</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Adjusted mean difference: tofersen minus placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">7.9 (−3.5 to 19.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Handheld dynamometry megascore</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Adjusted mean change from VALOR baseline</td><td class="xxxx-borders shading">–0.37</td><td class="xxxr-borders shading">–0.34</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Adjusted mean difference: tofersen minus placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">0.02 (–0.21 to 0.26)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Death or permanent ventilation</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of events/total no. of participants (%)</td><td class="xxxx-borders">2/21 (10)</td><td class="xxxr-borders">4/39 (10)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Hazard ratio (95% CI)<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">1.39 (0.22 to 8.80)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Death</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of events/total no. of participants (%)</td><td class="xxxx-borders shading">0/21</td><td class="xxxr-borders shading">1/39 (3)</td></tr><tr data-type="row"><td class="xblx-borders hanging12">Hazard ratio (95% CI)<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xbxx-borders">&nbsp;</td><td class="xbxr-borders" data-xml-align="center">NE (NE to NE)</td></tr></tbody></table></div><figcaption><div class="caption">Primary and Secondary End Points in VALOR in the Faster-Progression Subgroup.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Shown are the results at the end of the placebo-controlled period (week 28). CSF denotes cerebrospinal fluid, NE could not be estimated, and SOD1 superoxide dismutase 1.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Sequential analysis failed at this point, and all subsequent secondary end points are considered to be not significantly different between trial groups.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">The hazard ratio is based on a Cox proportional-hazards model adjusted for baseline disease duration since symptom onset, baseline ALSFRS-R score, and use of riluzole or edaravone.</div></div></div></figcaption></figure></div></section><section id="sec-2-2-2"><h4>Secondary End Points in VALOR</h4><div role="paragraph">Because statistical significance was not achieved for the primary end point, all subsequent differences between tofersen and placebo in the faster-progression subgroup are considered to be not significantly different, and no P values are presented. In the faster-progression subgroup, the total concentration of SOD1 protein in CSF was reduced by 29% in participants who received tofersen (geometric mean ratio to baseline, 0.71; 95% CI, 0.62 to 0.83), as compared with an increase of 16% (geometric mean ratio to baseline, 1.16; 95% CI, 0.96 to 1.40) in those who received placebo (between-group difference in geometric mean ratio, 0.62; 95% CI, 0.49 to 0.78) (<a href="#t2">Table 2</a>). The total concentration of SOD1 protein in CSF was reduced by 40% in the tofersen-treated slower-progression subgroup, as compared with a reduction by 19% in the participants in the slower-progression subgroup who received placebo (between-group difference in geometric mean ratio, 0.74; 95% CI, 0.63 to 0.88) (Table S4). The mean concentration of neurofilament light chains in plasma was reduced by 60% in the tofersen-treated faster-progression subgroup and increased 20% with placebo (between-group difference in geometric mean ratio, 0.33; 95% CI, 0.25 to 0.45) (<a href="#t2">Table 2</a>).</div><div role="paragraph">In the faster-progression subgroup, the percentage of predicted slow vital capacity declined by 14.3 points from baseline to week 28 among participants who received tofersen and declined by 22.2 points among those who received placebo (difference, 7.9 percentage points; 95% CI, –3.5 to 19.3) (<a href="#t2">Table 2</a>). The change from baseline to week 28 in handheld dynamometry megascore was −0.34 in the tofersen group and −0.37 in the placebo group (difference, 0.02; 95% CI, –0.21 to 0.26). The median time to death or permanent ventilation could not be estimated owing to the small number of events; no difference was observed in the percentage of participants who died or required permanent ventilation in the tofersen group (10%) or in the placebo group (10%) (hazard ratio, 1.39; 95% CI, 0.22 to 8.80). The median time to death could not be estimated, with one event (3% of participants) in the tofersen group and no events in the placebo group (<a href="#t2">Table 2</a>). Descriptive analyses in the slower-progression subgroup during VALOR are provided in Table S4.</div></section></section><section id="sec-2-3"><h3>Combined VALOR and Open-Label Extension</h3><div role="paragraph">After completion of VALOR, 95 participants (88%) were enrolled in the nonrandomized open-label extension, with 63 (88%) originally assigned to receive tofersen and 32 (89%) originally assigned to receive placebo. At the time of the most recent data cutoff (January 16, 2022), 49 participants (68%) in the early-start cohort and 18 (50%) in the delayed-start cohort remained in the open-label extension. All 108 participants who underwent randomization in VALOR were included in the analysis of the combined data set for VALOR and the open-label extension, whether they were previously included as part of the faster-progression or slower-progression subgroup. In early-start participants, reductions in the total SOD1 concentration in CSF and the concentration of neurofilament light chains in plasma were numerically sustained over time; delayed-start participants had similar reductions during the open-label extension (<a href="#f1">Figure 1</a>). At 52 weeks, the change in the ALSFRS-R score from the VALOR baseline was −6.0 points for early-start participants and −9.5 points for delayed-start participants (difference, 3.5 points; 95% CI, 0.4 to 6.7). Imputation for week 52 was required for missing data in 15 participants (21%) in the early-start cohort and 8 participants (22%) in the delayed-start cohort (<a href="#f2">Figure 2</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204705_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204705_f1.jpg"><img src="/cms/10.1056/NEJMoa2204705/asset/c78fcb78-95c7-40a8-a925-d1a698faec93/assets/images/large/nejmoa2204705_f1.jpg" height="3437" width="2231" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Total Superoxidase Dismutase 1 (SOD1) Concentrations in Cerebrospinal Fluid (CSF) and Concentrations of Neurofilament Light Chains (NfL) in Plasma.</div><div class="notes"><div role="doc-footnote">Shown is the course of all randomly assigned participants (intention-to-treat population) over a period of 52 weeks, including those with faster-progressing disease and those with slower-progressing disease. After completing the 28-week placebo-controlled period, all the participants had the opportunity to receive tofersen in the open-label extension. Participants who initiated tofersen at week 0 in the VALOR component of the trial make up the “early-start cohort,” and those who received placebo in VALOR and had the opportunity to cross over to tofersen in the open-label extension are referred to as the “delayed-start cohort.” Participant disposition is summarized in Figure S3 in the <a href="#ap2">Supplementary Appendix</a>. 𝙸 bars represent 95% confidence intervals.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204705_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204705_f2.jpg"><img src="/cms/10.1056/NEJMoa2204705/asset/32ba9148-545e-4d73-be9c-547bc4459e1d/assets/images/large/nejmoa2204705_f2.jpg" height="3438" width="1502" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Analyses of Clinical Function and Survival.</div><div class="notes"><div role="doc-footnote">Shown is the course of all randomly assigned participants (intention-to-treat population). Panels A, B, and C reflect data over a period of 52 weeks since VALOR baseline. Panel D reflects all available follow-up data from VALOR baseline to the data-cutoff date of the open-label extension (January 16, 2022). After completing the 28-week placebo-controlled period, all the participants had the opportunity to receive tofersen in the open-label extension. Participants who initiated tofersen at week 0 in the VALOR component of the trial make up the “early-start cohort,” and those who received placebo in VALOR and had the opportunity to cross over to tofersen in the open-label extension are referred to as the “delayed-start cohort.” Participant disposition is summarized in Figure S3. Numerical results at 52 weeks were not adjusted for multiple comparisons. Total scores on the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R) (Panel A) range from 0 to 48, with higher scores indicating better function. The handheld dynamometry megascore (Panel C) is the average of z-scores across 16 muscle groups in the arms and legs, with higher values indicating greater strength. 𝙸 bars represent standard errors.</div></div></figcaption></figure></div><div role="paragraph">The change in the percentage of predicted slow vital capacity from the VALOR baseline was −9.4% for early-start participants and −18.6% for delayed-start participants (difference, 9.2 percentage points; 95% CI, 1.7 to 16.6). The change in handheld dynamometry megascore from the VALOR baseline was −0.17 for early-start participants and −0.45 for delayed-start participants (difference, 0.28; 95% CI, 0.05 to 0.52). <a href="#f2">Figure 2</a> and Table S5 show the results of the ALSFRS-R score, the percentage of predicted slow vital capacity, and the handheld dynamometry megascore for the combined analyses of VALOR and the open-label extension.</div><div role="paragraph">The median time to death or permanent ventilation and the median time to death could not be estimated owing to the limited number of events. For early-start participants as compared with delayed-start participants, the hazard ratio for time to death or permanent ventilation was 0.36 (95% CI, 0.14 to 0.94), and the hazard ratio for time to death was 0.27 (95% CI, 0.08 to 0.89) (Table S5). In a descriptive analysis, the disease duration in the 16 participants of special interest with p.Ala5Val mutations who received tofersen was a median of 1.73 years (range, 0.88 to 3.68), with 3 of these participants remaining in the trial at the time of the data cutoff (range for the 3 ongoing participants, 1.89 to 3.68 years) (Fig. S4).</div></section><section id="sec-2-4"><h3>Safety and Adverse Events</h3><div role="paragraph">Most adverse events across VALOR and the open-label extension were mild to moderate in severity and did not cause withdrawal or discontinuation of the trial agent. Most adverse events were consistent with ALS disease progression, conditions in the general population, or known side effects of lumbar puncture (<a href="#t3">Table 3</a>). The most common adverse events included procedural pain, headache, pain in the arms or legs, falls, and back pain. In VALOR, the incidence of procedural pain and headache were similar among participants who received tofersen and among those who received placebo, whereas pain in the arms or legs and back pain were more common in the tofersen group (incidence higher by ≥5 percentage points) and falls were more common in the placebo group.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204705_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204705_t3.jpg"><img src="/cms/10.1056/NEJMoa2204705/asset/b5e5107f-e3cd-4ebd-ade8-3995088860e7/assets/images/large/nejmoa2204705_t3.jpg" height="2434" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Adverse Event</th><th class="txxx-borders" colspan="2"><span>VALOR</span></th><th class="txxr-borders">VALOR and Open-Label Extension Combined<a href="#t3fn2" role="doc-noteref">†</a></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Placebo<br>(N=36)</th><th class="xxxx-borders">Tofersen<br>(N=72)<a href="#t3fn2" role="doc-noteref">†</a></th><th class="xxxr-borders">Tofersen<br>(N=104)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="3"><span>number of participants (percent)<a href="#t3fn3" role="doc-noteref">‡</a></span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any event</td><td class="xxxx-borders shading">34 (94)</td><td class="xxxx-borders shading">69 (96)</td><td class="xxxr-borders shading">102 (98)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Event related to trial agent<a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">28 (39)</td><td class="xxxr-borders">63 (61)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Event related to lumbar puncture<a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">29 (81)</td><td class="xxxx-borders shading">58 (81)</td><td class="xxxr-borders shading">84 (81)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serious event</td><td class="xxxx-borders">5 (14)</td><td class="xxxx-borders">13 (18)</td><td class="xxxr-borders">38 (37)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious event related to trial agent<a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">4 (6)</td><td class="xxxr-borders shading">7 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Event with fatal outcome</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">14 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Events leading to discontinuation of trial agent</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">4 (6)</td><td class="xxxr-borders shading">18 (17)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Adverse events occurring in ≥15% of participants in combined analysis<a href="#t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Headache</td><td class="xxxx-borders shading">16 (44)</td><td class="xxxx-borders shading">33 (46)</td><td class="xxxr-borders shading">58 (56)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Procedural pain</td><td class="xxxx-borders">21 (58)</td><td class="xxxx-borders">41 (57)</td><td class="xxxr-borders">56 (54)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Fall</td><td class="xxxx-borders shading">15 (42)</td><td class="xxxx-borders shading">17 (24)</td><td class="xxxr-borders shading">40 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Back pain</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">15 (21)</td><td class="xxxr-borders">39 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pain in arm or leg</td><td class="xxxx-borders shading">6 (17)</td><td class="xxxx-borders shading">19 (26)</td><td class="xxxr-borders shading">38 (37)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Arthralgia</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">10 (14)</td><td class="xxxr-borders">28 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">CSF protein concentration increased</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">6 (8)</td><td class="xxxr-borders shading">24 (23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Fatigue</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">12 (17)</td><td class="xxxr-borders">24 (23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Post–lumbar puncture syndrome</td><td class="xxxx-borders shading">11 (31)</td><td class="xxxx-borders shading">13 (18)</td><td class="xxxr-borders shading">22 (21)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Myalgia</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">10 (14)</td><td class="xxxr-borders">21 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">CSF white-cell count increased</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">7 (10)</td><td class="xxxr-borders shading">19 (18)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nausea</td><td class="xxxx-borders">6 (17)</td><td class="xxxx-borders">9 (12)</td><td class="xxxr-borders">17 (16)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">4 (11)</td><td class="xxxx-borders shading">6 (8)</td><td class="xxxr-borders shading">17 (16)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Pyrexia</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">3 (4)</td><td class="xxxr-borders">16 (15)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Serious adverse events occurring in ≥2% of participants in combined analysis<a href="#t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Respiratory failure</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">10 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pneumonia aspiration</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (3)</td><td class="xxxr-borders shading">9 (9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Pulmonary embolism</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">3 (4)</td><td class="xxxr-borders">4 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Acute respiratory failure</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">4 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Dysphagia</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxr-borders">3 (3)</td></tr></tbody></table></div><figcaption><div class="caption">Summary of Adverse Events.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Shown are events that had an onset date on or after the start of the trial agent or that worsened after the start of the trial agent.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">An event in a participant who received placebo during VALOR is counted only once. An event in a participant who received tofersen during VALOR is counted in both columns for tofersen.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">A participant could appear in more than one category.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t3fn4" role="paragraph">The relatedness of an event to the trial agent or lumbar puncture was assessed by the investigator.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t3fn5" role="paragraph">A participant is counted only once for each preferred term (<i>Medical Dictionary for Regulatory Activities</i>, version 24.0).</div></div></div></figcaption></figure></div><div role="paragraph">Four participants who received tofersen in VALOR (6%) and three participants in the open-label extension (constituting 7% of all participants who received tofersen) had a total of eight neurologic serious adverse events, including myelitis, chemical or aseptic meningitis, lumbar radiculopathy, increased intracranial pressure, and papilledema. The participant with myelitis was hospitalized approximately 1 week after the fifth dose of tofersen, received glucocorticoids and plasma exchange, and received no further trial treatment. Within 3 months after the last dose of tofersen, this participant had resolution of neurologic signs, symptoms, and findings on imaging.</div><div role="paragraph">In VALOR, 42 participants (58%) in the tofersen group and 2 participants (6%) in the placebo group had at least one CSF white-cell count of more than 10 cells per cubic millimeter, and approximately 40% of the participants had elevated CSF protein concentrations at baseline. The median CSF protein concentration increased by 110 mg per liter in the tofersen group and decreased by 15 mg per liter in the placebo group. Similar incidences of CSF pleocytosis and elevated protein concentrations were observed during the open-label extension.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In the 28-week randomized VALOR component of the trial, tofersen was associated with reductions in the total concentration of SOD1 protein in CSF, an indirect marker of target engagement, and the concentration of neurofilament light chains in plasma, a marker of axonal injury and neurodegeneration. Despite these results, no significant difference was seen at 28 weeks in the change from baseline in the ALSFRS-R score between tofersen and placebo in a subgroup predicted to have faster progression, and no definitive differences were seen in other clinical end points in this subgroup. At 52 weeks in a prespecified combined analysis of VALOR and its open-label extension, participants who started tofersen at the beginning of VALOR, irrespective of fast or slow progression, had a smaller numeric decline in the ALSFRS-R score, the percentage of predicted slow vital capacity, and handheld dynamometry megascore than those who started tofersen in the open-label extension 28 weeks later. Limitations in interpreting the results of the combined analysis include the absence of adjustment of the widths of confidence intervals for multiple comparisons in the analysis of differences between the early-start and delayed-start cohorts, approximately 20% of missing end-point data that required imputation, and the results of the VALOR component of the trial being known at the time of analysis.</div><div role="paragraph">Neurologic serious adverse events, including myelitis, chemical or aseptic meningitis, lumbar radiculopathy, increased intracranial pressure, and papilledema, occurred in approximately 7% of the participants receiving tofersen. The underlying mechanism of myelitis and the relationship to CSF pleocytosis and protein elevations could not be established.</div><div role="paragraph">At the time that the trial was designed, <i>SOD1</i> mutation type and prerandomization ALSFRS-R slope were considered to be appropriate tools for addressing the heterogeneity of disease progression in <i>SOD1</i> ALS, but neither is consistently prognostic over a short trial period. Although the prognostic usefulness of neurofilament light chains had been characterized at that time, assay limitations precluded randomization according to an individual participant’s baseline concentration of neurofilament light chains, which would have enabled better balance across trial groups. Instead, subgroup analyses were prespecified in our trial and defined according to the median baseline concentration of neurofilament light chains. This approach helped to address imbalances in baseline characteristics (concentration of neurofilament light chains in plasma and ALSFRS-R decline from screening to day 15) but made use of arbitrary subgrouping rather than controlling for each participant’s baseline concentration of neurofilament light chains (see Section S2 in the <a href="#ap2">Supplementary Appendix</a>). To address individual disease heterogeneity, the baseline concentration of neurofilament light chains in plasma was incorporated as a covariate across analyses. This alteration to the analysis plan was specified after the VALOR results and initial results from the combined VALOR and open-label extension were available but before the latest combined analysis was conducted. As testing of neurofilament light chains becomes more readily available, randomization based on the concentration of neurofilament light chains in plasma as a continuous variable may be considered in future ALS clinical trials.</div><div role="paragraph">The duration and size of VALOR were determined on the basis of available but limited data from 12 <i>SOD1</i> mutation carriers with rapidly progressing disease who received placebo in the tofersen phase 1–2 multiple-ascending-dose study<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15-3" href-manipulated="true" aria-label="Reference 15">15</a></sup> and the phase 2 trial of arimoclomol, a heat-shock protein coinducer that promotes nascent protein folding.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25" href-manipulated="true" aria-label="Reference 25">25</a></sup> These persons had a rapid decline in function over the period of these studies. In contrast, the participants who received placebo in the enriched faster-progression subgroup in VALOR had declines that were three times as slow as those projected by the data.</div><div role="paragraph">The possible signal of differences in clinical end points between the early-start and delayed-start cohorts in the combined analysis of VALOR and the open-label extension, with the limitations mentioned, suggests that a trial duration of more than 28 weeks may be required to determine the effect of tofersen in patients with this disorder.<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26 r27" id="body-ref-r27" href-manipulated="true">26,27</a></sup> Earlier or presymptomatic intervention is being investigated in the ongoing ATLAS trial (ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT04856982" target="_blank">NCT04856982</a>).<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28" id="body-ref-r28" href-manipulated="true" aria-label="Reference 28">28</a></sup></div><div role="paragraph">In the 28-week VALOR component of this trial of intrathecal administration of the antisense oligonucleotide tofersen in patients with <i>SOD1</i> ALS, there was not a significant difference in the decline on a composite measure of ALS progression as compared with placebo. Tofersen was associated in a limited number of participants with adverse events, including myelitis. The potential effects of earlier as compared with delayed initiation of tofersen are being further evaluated in the ongoing extension phase.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Biogen</span>.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the participants in VALOR and the open-label extension and their families and caregivers, without whom this trial would not have been possible; members of global patient advocacy organizations; site staff (see the <a href="#ap2">Supplementary Appendix</a>); Christine Nelson, Pharm.D. (Biogen), and Yien Liu, Ph.D. (Excel Scientific Solutions), for medical writing assistance with earlier versions of the manuscript; and Cara Dickinson, B.A. (Excel Scientific Solutions), for assistance with copyediting and styling of an earlier version of the manuscript in accordance with <i>Journal</i> requirements.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2204705_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2204705/suppl_file/nejmoa2204705_research-summary.pdf" download="nejmoa2204705_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2204705_research-summary.pdf" data-doi="10.1056/NEJMoa2204705">Download</a></li><li>367.31 KB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2204705_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2204705/suppl_file/nejmoa2204705_protocol.pdf" download="nejmoa2204705_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2204705_protocol.pdf" data-doi="10.1056/NEJMoa2204705">Download</a></li><li>18.99 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2204705_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2204705/suppl_file/nejmoa2204705_appendix.pdf" download="nejmoa2204705_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2204705_appendix.pdf" data-doi="10.1056/NEJMoa2204705">Download</a></li><li>738.79 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2204705_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2204705/suppl_file/nejmoa2204705_disclosures.pdf" download="nejmoa2204705_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2204705_disclosures.pdf" data-doi="10.1056/NEJMoa2204705">Download</a></li><li>1.05 MB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2204705_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2204705/suppl_file/nejmoa2204705_data-sharing.pdf" download="nejmoa2204705_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2204705_data-sharing.pdf" data-doi="10.1056/NEJMoa2204705">Download</a></li><li>91.28 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Bunton-Stasyshyn RK, Saccon RA, Fratta P, Fisher EM. SOD1 function and its implications for amyotrophic lateral sclerosis pathology: new and renascent themes. <em>Neuroscientist</em> 2015;21:519-529.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/1073858414561795" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25492944/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000362290000011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SOD1+function+and+its+implications+for+amyotrophic+lateral+sclerosis+pathology%3A+new+and+renascent+themes.&amp;publication_year=2015&amp;journal=Neuroscientist&amp;pages=519-529&amp;doi=10.1177%2F1073858414561795&amp;pmid=25492944" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] SOD1). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of function of the mutant SOD1 protein. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Müller K, Brenner D, Weydt P, et al. Comprehensive analysis of the mutation spectrum in 301 German ALS families. <em>J Neurol Neurosurg Psychiatry</em> 2018;89:817-827.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/jnnp-2017-317611" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29650794/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000442475000013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comprehensive+analysis+of+the+mutation+spectrum+in+301+German+ALS+families.&amp;publication_year=2018&amp;journal=J+Neurol+Neurosurg+Psychiatry&amp;pages=817-827&amp;doi=10.1136%2Fjnnp-2017-317611&amp;pmid=29650794" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Huai J, Zhang Z. Structural properties and interaction partners of familial ALS-associated SOD1 mutants. <em>Front Neurol</em> 2019;10:527-527.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3389/fneur.2019.00527" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31164862/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000468416400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Structural+properties+and+interaction+partners+of+familial+ALS-associated+SOD1+mutants.&amp;publication_year=2019&amp;journal=Front+Neurol&amp;pages=527-527&amp;doi=10.3389%2Ffneur.2019.00527&amp;pmid=31164862" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Bali T, Self W, Liu J, et al. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. <em>J Neurol Neurosurg Psychiatry</em> 2017;88:99-105.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/jnnp-2016-313521" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27261500/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393903700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Defining+SOD1+ALS+natural+history+to+guide+therapeutic+clinical+trial+design.&amp;publication_year=2017&amp;journal=J+Neurol+Neurosurg+Psychiatry&amp;pages=99-105&amp;doi=10.1136%2Fjnnp-2016-313521&amp;pmid=27261500" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Amyotrophic Lateral Sclerosis online Database. SOD1 gene summary (<a href="https://alsod.ac.uk/output/gene.php/SOD1">https://alsod.ac.uk/output/gene.php/SOD1</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SOD1+gene+summary" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Hayashi Y, Homma K, Ichijo H. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS. <em>Adv Biol Regul</em> 2016;60:95-104.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jbior.2015.10.006" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26563614/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SOD1+in+neurotoxicity+and+its+controversial+roles+in+SOD1+mutation-negative+ALS.&amp;publication_year=2016&amp;journal=Adv+Biol+Regul&amp;pages=95-104&amp;doi=10.1016%2Fj.jbior.2015.10.006&amp;pmid=26563614" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Coppedè F, Stoccoro A, Mosca L, et al. Increase in DNA methylation in patients with amyotrophic lateral sclerosis carriers of not fully penetrant SOD1 mutations. <em>Amyotroph Lateral Scler Frontotemporal Degener</em> 2018;19:93-101.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/21678421.2017.1367401" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28859526/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000425671500014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Increase+in+DNA+methylation+in+patients+with+amyotrophic+lateral+sclerosis+carriers+of+not+fully+penetrant+SOD1+mutations.&amp;publication_year=2018&amp;journal=Amyotroph+Lateral+Scler+Frontotemporal+Degener&amp;pages=93-101&amp;doi=10.1080%2F21678421.2017.1367401&amp;pmid=28859526" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Ekhtiari Bidhendi E, Bergh J, Zetterström P, et al. Mutant superoxide dismutase aggregates from human spinal cord transmit amyotrophic lateral sclerosis. <em>Acta Neuropathol</em> 2018;136:939-953.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00401-018-1915-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30284034/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000451952700008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mutant+superoxide+dismutase+aggregates+from+human+spinal+cord+transmit+amyotrophic+lateral+sclerosis.&amp;publication_year=2018&amp;journal=Acta+Neuropathol&amp;pages=939-953&amp;doi=10.1007%2Fs00401-018-1915-y&amp;pmid=30284034" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. <em>J Cell Biol</em> 2009;187:761-772.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1083/jcb.200908164" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19951898/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000272702500004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Non-cell+autonomous+toxicity+in+neurodegenerative+disorders%3A+ALS+and+beyond.&amp;publication_year=2009&amp;journal=J+Cell+Biol&amp;pages=761-772&amp;doi=10.1083%2Fjcb.200908164&amp;pmid=19951898" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">McCampbell A, Cole T, Wegener AJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. <em>J Clin Invest</em> 2018;128:3558-3567.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI99081" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30010620/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000440461500036" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antisense+oligonucleotides+extend+survival+and+reverse+decrement+in+muscle+response+in+ALS+models.&amp;publication_year=2018&amp;journal=J+Clin+Invest&amp;pages=3558-3567&amp;doi=10.1172%2FJCI99081&amp;pmid=30010620" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of function of the mutant SOD1 protein. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] messenger RNA. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Saccon RA, Bunton-Stasyshyn RK, Fisher EM, Fratta P. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? <em>Brain</em> 2013;136:2342-2358.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/brain/awt097" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23687121/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000322338000009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Is+SOD1+loss+of+function+involved+in+amyotrophic+lateral+sclerosis%3F&amp;publication_year=2013&amp;journal=Brain&amp;pages=2342-2358&amp;doi=10.1093%2Fbrain%2Fawt097&amp;pmid=23687121" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Sau D, De Biasi S, Vitellaro-Zuccarello L, et al. Mutation of SOD1 in ALS: a gain of a loss of function. <em>Hum Mol Genet</em> 2007;16:1604-1618.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/hmg/ddm110" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17504823/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000248447200009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mutation+of+SOD1+in+ALS%3A+a+gain+of+a+loss+of+function.&amp;publication_year=2007&amp;journal=Hum+Mol+Genet&amp;pages=1604-1618&amp;doi=10.1093%2Fhmg%2Fddm110&amp;pmid=17504823" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. <em>Nat Rev Neurol</em> 2018;14:9-21.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrneurol.2017.148" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29192260/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423052600009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antisense+oligonucleotides%3A+the+next+frontier+for+treatment+of+neurological+disorders.&amp;publication_year=2018&amp;journal=Nat+Rev+Neurol&amp;pages=9-21&amp;doi=10.1038%2Fnrneurol.2017.148&amp;pmid=29192260" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. <em>J Clin Invest</em> 2006;116:2290-2296.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI25424" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16878173/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000239499300031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antisense+oligonucleotide+therapy+for+neurodegenerative+disease.&amp;publication_year=2006&amp;journal=J+Clin+Invest&amp;pages=2290-2296&amp;doi=10.1172%2FJCI25424&amp;pmid=16878173" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1–2 trial of antisense oligonucleotide tofersen for <i>SOD1</i> ALS. <em>N Engl J Med</em> 2020;383:109-119.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_16_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2204705&amp;key=10.1056%2FNEJMoa2003715&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32640130/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000571894800010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+1%E2%80%932+trial+of+antisense+oligonucleotide+tofersen+for+SOD1+ALS.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=109-119&amp;doi=10.1056%2FNEJMoa2003715&amp;pmid=32640130" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] messenger RNA. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the full text of this article at NEJM.org). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] phase 1–2 multiple-ascending-dose study </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Abu-Rumeileh S, Vacchiano V, Zenesini C, et al. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. <em>J Neurol</em> 2020;267:1699-1708.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00415-020-09761-z" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32100123/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000515910200003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnostic-prognostic+value+and+electrophysiological+correlates+of+CSF+biomarkers+of+neurodegeneration+and+neuroinflammation+in+amyotrophic+lateral+sclerosis.&amp;publication_year=2020&amp;journal=J+Neurol&amp;pages=1699-1708&amp;doi=10.1007%2Fs00415-020-09761-z&amp;pmid=32100123" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] from March 2019 through July 2021. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] a prognostic marker of disease progression, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. <em>Neurology</em> 2020;95(1):e59-e69.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0000000000009559" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32385188/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000559750000015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Validation+of+serum+neurofilaments+as+prognostic+and+potential+pharmacodynamic+biomarkers+for+ALS.&amp;publication_year=2020&amp;journal=Neurology&amp;pages=e59-e69&amp;doi=10.1212%2FWNL.0000000000009559&amp;pmid=32385188" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">De Schaepdryver M, Lunetta C, Tarlarini C, et al. Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis. <em>J Neurol Neurosurg Psychiatry</em> 2020;91:436-437.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/jnnp-2019-322309" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32029541/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000523679000017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Neurofilament+light+chain+and+C+reactive+protein+explored+as+predictors+of+survival+in+amyotrophic+lateral+sclerosis.&amp;publication_year=2020&amp;journal=J+Neurol+Neurosurg+Psychiatry&amp;pages=436-437&amp;doi=10.1136%2Fjnnp-2019-322309&amp;pmid=32029541" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Gaiani A, Martinelli I, Bello L, et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. <em>JAMA Neurol</em> 2017;74:525-532.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamaneurol.2016.5398" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28264096/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400838900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnostic+and+prognostic+biomarkers+in+amyotrophic+lateral+sclerosis%3A+neurofilament+light+chain+levels+in+definite+subtypes+of+disease.&amp;publication_year=2017&amp;journal=JAMA+Neurol&amp;pages=525-532&amp;doi=10.1001%2Fjamaneurol.2016.5398&amp;pmid=28264096" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. <em>Neurology</em> 2015;84:2247-2257.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0000000000001642" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25934855/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000360568500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Neurofilament+light+chain%3A+a+prognostic+biomarker+in+amyotrophic+lateral+sclerosis.&amp;publication_year=2015&amp;journal=Neurology&amp;pages=2247-2257&amp;doi=10.1212%2FWNL.0000000000001642&amp;pmid=25934855" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. <em>Front Neurol</em> 2019;9:1167-1167.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3389/fneur.2018.01167" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30713520/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000455992900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnostic+and+prognostic+performance+of+neurofilaments+in+ALS.&amp;publication_year=2019&amp;journal=Front+Neurol&amp;pages=1167-1167&amp;doi=10.3389%2Ffneur.2018.01167&amp;pmid=30713520" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. <em>J Neurol Neurosurg Psychiatry</em> 2016;87:12-20.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26296871/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000366732700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Neurofilaments+in+the+diagnosis+of+motoneuron+diseases%3A+a+prospective+study+on+455+patients.&amp;publication_year=2016&amp;journal=J+Neurol+Neurosurg+Psychiatry&amp;pages=12-20&amp;pmid=26296871" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Thompson AG, Gray E, Verber N, et al. Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. <em>Brain Commun</em> 2022;4:fcac029-fcac029.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/braincomms/fcac029" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35224491/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Multicentre+appraisal+of+amyotrophic+lateral+sclerosis+biofluid+biomarkers+shows+primacy+of+blood+neurofilament+light+chain.&amp;publication_year=2022&amp;journal=Brain+Commun&amp;pages=fcac029-fcac029&amp;doi=10.1093%2Fbraincomms%2Ffcac029&amp;pmid=35224491" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. <em>J Neurol Neurosurg Psychiatry</em> 2019;90:157-164.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/jnnp-2018-318704" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30309882/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000471112000009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Neurofilament+light+chain+in+serum+for+the+diagnosis+of+amyotrophic+lateral+sclerosis.&amp;publication_year=2019&amp;journal=J+Neurol+Neurosurg+Psychiatry&amp;pages=157-164&amp;doi=10.1136%2Fjnnp-2018-318704&amp;pmid=30309882" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Benatar M, Wuu J, Andersen PM, et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive <i>SOD1</i> ALS. <em>Neurology</em> 2018;90(7):e565-e574.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0000000000004960" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29367439/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000427813200004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized%2C+double-blind%2C+placebo-controlled+trial+of+arimoclomol+in+rapidly+progressive+SOD1+ALS.&amp;publication_year=2018&amp;journal=Neurology&amp;pages=e565-e574&amp;doi=10.1212%2FWNL.0000000000004960&amp;pmid=29367439" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Ludolph AC, Dorst J, Dreyhaupt J, et al. Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. <em>Ann Neurol</em> 2020;87:206-216.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ana.25661" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31849093/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505602400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+high-caloric+nutrition+on+survival+in+amyotrophic+lateral+sclerosis.&amp;publication_year=2020&amp;journal=Ann+Neurol&amp;pages=206-216&amp;doi=10.1002%2Fana.25661&amp;pmid=31849093" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Ludolph AC, Schuster J, Dorst J, et al. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. <em>Lancet Neurol</em> 2018;17:681-688.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(18)30176-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29934198/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000439057500012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+rasagiline+as+an+add-on+therapy+to+riluzole+in+patients+with+amyotrophic+lateral+sclerosis%3A+a+randomised%2C+double-blind%2C+parallel-group%2C+placebo-controlled%2C+phase+2+trial.&amp;publication_year=2018&amp;journal=Lancet+Neurol&amp;pages=681-688&amp;doi=10.1016%2FS1474-4422%2818%2930176-5&amp;pmid=29934198" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Benatar M, Wuu J, Andersen PM, et al. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. <em>Neurotherapeutics</em> 2022 May 18 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s13311-022-01237-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35585374/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000797294200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Design+of+a+randomized%2C+placebo-controlled%2C+phase+3+trial+of+tofersen+initiated+in+clinically+presymptomatic+SOD1+variant+carriers%3A+the+ATLAS+study.&amp;publication_year=2022&amp;journal=Neurotherapeutics&amp;doi=10.1007%2Fs13311-022-01237-4&amp;pmid=35585374" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/387/12"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">387</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">12</span></span> • <span property="datePublished">September 22, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1099</span>-<span property="pageEnd">1110</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: September 21, 2022</div><div><b class="core-label">Published in issue</b>: September 22, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/genetics-general" alt="View article keyword Genetics General" data-interactiontype="article_recirculation_click">Genetics General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/neuromuscular-disease" alt="View article keyword Neuromuscular Disease" data-interactiontype="article_recirculation_click">Neuromuscular Disease</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Timothy M.</span> <span property="familyName">Miller</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Merit E.</span> <span property="familyName">Cudkowicz</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Angela</span> <span property="familyName">Genge</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Pamela J.</span> <span property="familyName">Shaw</span>, <span property="honorificSuffix">M.B., B.S., M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Gen</span> <span property="familyName">Sobue</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Robert C.</span> <span property="familyName">Bucelli</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Adriano</span> <span property="familyName">Chiò</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Philip</span> <span property="familyName">Van Damme</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Albert C.</span> <span property="familyName">Ludolph</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jonathan D.</span> <span property="familyName">Glass</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jinsy A.</span> <span property="familyName">Andrews</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Suma</span> <span property="familyName">Babu</span>, <span property="honorificSuffix">M.B., B.S., M.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Michael</span> <span property="familyName">Benatar</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-4241-5135" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-4241-5135</a></span>, <span property="author" typeof="Person"><span property="givenName">Christopher J.</span> <span property="familyName">McDermott</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Thos</span> <span property="familyName">Cochrane</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sowmya</span> <span property="familyName">Chary</span>, <span property="honorificSuffix">M.B., B.S., M.M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sheena</span> <span property="familyName">Chew</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Han</span> <span property="familyName">Zhu</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Fan</span> <span property="familyName">Wu</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ivan</span> <span property="familyName">Nestorov</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Danielle</span> <span property="familyName">Graham</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Peng</span> <span property="familyName">Sun</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Manjit</span> <span property="familyName">McNeill</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Laura</span> <span property="familyName">Fanning</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Toby A.</span> <span property="familyName">Ferguson</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Stephanie</span> <span property="familyName">Fradette</span>, <span property="honorificSuffix">Pharm.D.</span></span>, for <span property="author" typeof="Person">the VALOR and OLE Working Group<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Washington University School of Medicine, St. Louis (T.M.M., R.C.B.); the Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.E.C., S.B.), and Biogen, Cambridge (T.C., S. Chary, S. Chew, H.Z., F.W., I.N., D.G., P.S., L.F., T.A.F., S.F.) — both in Massachusetts; Montreal Neurological Institute and Hospital, Montreal (A.G.); the Sheffield Institute for Translational Neuroscience, University of Sheffield, and the National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) — both in the United Kingdom; Aichi Medical University, Aichi, Japan (G.S.); the University of Turin, Turin, Italy (A.C.); KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.); the University of Ulm, Ulm, and Deutsches Zentrum für Neurodegenerative Erkrankungen, Bonn — both in Germany (A.C.L.); Emory University, Atlanta (J.D.G.); the Neurological Institute, Columbia University Irving Medical Center, New York (J.A.A.); and the Department of Neurology, University of Miami, Miami (M.B.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. Miller can be contacted at <a href="mailto:miller.t@wustl.edu">miller.t@wustl.edu</a> or at the Department of Neurology, Washington University School of Medicine, 660 S. Euclid Ave., Box 8111, St. Louis, MO 63110. Dr. Fradette can be contacted at <a href="mailto:stephanie.fradette@biogen.com">stephanie.fradette@biogen.com</a> or at Biogen, 225 Binney St., Cambridge, MA 02142.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">The members of the VALOR and OLE Working Group are listed in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">510</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2204705" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="4227b763-c99e-b33a-025c-152faeccdbe6"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230356" style="display:inline-block;">
                <img alt="Article has an altmetric score of 1618" src="https://badges.altmetric.com/?size=320&amp;score=1618&amp;types=mabcrtwf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230356">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_4227b763-c99e-b33a-025c-152faeccdbe6" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230356&amp;tab=news">
          Picked up by <b>201</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230356&amp;tab=blogs">
          Blogged by <b>5</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230356&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230356&amp;tab=twitter">
          Posted by <b>174</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230356&amp;tab=patents">
          Referenced in <b>1</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230356&amp;tab=facebook">
          On <b>2</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230356&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230356&amp;tab=reddit">
          Reddited by <b>2</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230356&amp;tab=guidelines">
          Referenced in <b>1</b> clinical guideline sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #70B1FF;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=136230356&amp;tab=bluesky">
          Referenced by <b>1</b> Bluesky users
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>697</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6eb9ff0710176-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2204705"> <input type="hidden" name="downloadFileName" value="csp_387_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-12%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2204705%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="510" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Michele L. Yang, </li><li class="list-inline-item cited-by__entry__author">Anne M. Connolly, </li></ul><span class="cited-by__entry__title">Other M­ot­or N­eu­ron Diseases o­f C­hi­ldhood, </span><span class="cited-by__entry__series-title">Swaiman's Pediatric Neurology, </span><span class="cited-by__entry__page-range">(1401-1410.e3), </span><span class="cited-by__entry__pub-date">(2026).</span><a href="https://doi.org/10.1016/B978-0-443-10944-7.00161-X" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/B978-0-443-10944-7.00161-X</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/B978-0-443-10944-7.00161-X" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Kaly A. Mueller, </li><li class="list-inline-item cited-by__entry__author">Emma G. Suneby, </li><li class="list-inline-item cited-by__entry__author">Matthew H. Ferola, </li><li class="list-inline-item cited-by__entry__author">Andy J. Moreno, </li><li class="list-inline-item cited-by__entry__author">Joshua D. Kidd, </li><li class="list-inline-item cited-by__entry__author">Kenneth Thompson, </li><li class="list-inline-item cited-by__entry__author">Fernando G. Vieira, </li><li class="list-inline-item cited-by__entry__author">Gregorio Valdez, </li><li class="list-inline-item cited-by__entry__author">Theo Hatzipetros, </li></ul><span class="cited-by__entry__title">Comprehensive characterization and validation of the Prp-hPFN1G118V mouse model: Guidelines for preclinical therapeutic testing for ALS, </span><span class="cited-by__entry__series-title">Neurobiology of Disease, </span><span class="cited-by__entry__volume"><strong>212</strong>, </span><span class="cited-by__entry__page-range">(106975), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.nbd.2025.106975" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.nbd.2025.106975</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.nbd.2025.106975" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yujing Chen, </li><li class="list-inline-item cited-by__entry__author">Sujuan Sun, </li><li class="list-inline-item cited-by__entry__author">Ninglu Gao, </li><li class="list-inline-item cited-by__entry__author">Zetai Bai, </li><li class="list-inline-item cited-by__entry__author">Wenfei Yu, </li><li class="list-inline-item cited-by__entry__author">Bing Zhao, </li><li class="list-inline-item cited-by__entry__author">Yan Yun, </li><li class="list-inline-item cited-by__entry__author">Xiaohan Sun, </li><li class="list-inline-item cited-by__entry__author">Pengfei Lin, </li><li class="list-inline-item cited-by__entry__author">Wei Li, </li><li class="list-inline-item cited-by__entry__author">Yuying Zhao, </li><li class="list-inline-item cited-by__entry__author">Chuanzhu Yan, </li><li class="list-inline-item cited-by__entry__author">Shuangwu Liu, </li></ul><span class="cited-by__entry__title">Proximity extension assay reveals serum inflammatory biomarkers in two amyotrophic lateral sclerosis cohorts, </span><span class="cited-by__entry__series-title">Neurobiology of Disease, </span><span class="cited-by__entry__volume"><strong>211</strong>, </span><span class="cited-by__entry__page-range">(106933), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.nbd.2025.106933" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.nbd.2025.106933</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.nbd.2025.106933" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Katarzyna Dudzisz, </li><li class="list-inline-item cited-by__entry__author">Ilona Wandzik, </li></ul><span class="cited-by__entry__title">Antisense oligonucleotides: A promising advancement in neurodegenerative disease treatment, </span><span class="cited-by__entry__series-title">European Journal of Pharmacology, </span><span class="cited-by__entry__volume"><strong>999</strong>, </span><span class="cited-by__entry__page-range">(177644), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ejphar.2025.177644" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ejphar.2025.177644</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ejphar.2025.177644" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Heba M. Mansour, </li><li class="list-inline-item cited-by__entry__author">Aiman S. El-Khatib, </li></ul><span class="cited-by__entry__title">Oligonucleotide-based therapeutics for neurodegenerative disorders: Focus on antisense oligonucleotides, </span><span class="cited-by__entry__series-title">European Journal of Pharmacology, </span><span class="cited-by__entry__volume"><strong>998</strong>, </span><span class="cited-by__entry__page-range">(177529), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ejphar.2025.177529" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ejphar.2025.177529</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ejphar.2025.177529" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Andreas Hermann, </li><li class="list-inline-item cited-by__entry__author">Johannes Prudlo, </li><li class="list-inline-item cited-by__entry__author">Elisabeth Kasper, </li><li class="list-inline-item cited-by__entry__author">Matthis Synofzik, </li><li class="list-inline-item cited-by__entry__author">Oliver Peters, </li><li class="list-inline-item cited-by__entry__author">Josef Priller, </li><li class="list-inline-item cited-by__entry__author">Elisabeth Dinter, </li><li class="list-inline-item cited-by__entry__author">Jens Wiltfang, </li><li class="list-inline-item cited-by__entry__author">Inga Zerr, </li><li class="list-inline-item cited-by__entry__author">Agnes Flöel, </li><li class="list-inline-item cited-by__entry__author">Katharina Bürger, </li><li class="list-inline-item cited-by__entry__author">Günter U. Höglinger, </li><li class="list-inline-item cited-by__entry__author">Johannes Levin, </li><li class="list-inline-item cited-by__entry__author">Emrah Düzel, </li><li class="list-inline-item cited-by__entry__author">Stefan Teipel, </li><li class="list-inline-item cited-by__entry__author">Lukas Beichert, </li><li class="list-inline-item cited-by__entry__author">Frederic Brosseron, </li><li class="list-inline-item cited-by__entry__author">Michael Wagner, </li><li class="list-inline-item cited-by__entry__author">Ingo Frommann, </li><li class="list-inline-item cited-by__entry__author">Alfredo Ramirez, </li><li class="list-inline-item cited-by__entry__author">Renat Yakupov, </li><li class="list-inline-item cited-by__entry__author">Matthias Schmid, </li><li class="list-inline-item cited-by__entry__author">Paul Lingor, </li><li class="list-inline-item cited-by__entry__author">Christian Haass, </li><li class="list-inline-item cited-by__entry__author">Annika Spottke, </li><li class="list-inline-item cited-by__entry__author">René Günther, </li><li class="list-inline-item cited-by__entry__author">Patrick Weydt, </li><li class="list-inline-item cited-by__entry__author">Manuela Neumann, </li><li class="list-inline-item cited-by__entry__author">Anja Schneider, </li></ul><span class="cited-by__entry__title">“The DESCRIBE-ALS-FTD study: a prospective multicenter observational study of the ALS-FTD spectrum”, </span><span class="cited-by__entry__series-title">Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, </span><span class="cited-by__entry__page-range">(1-9), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/21678421.2025.2509617" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/21678421.2025.2509617</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/21678421.2025.2509617" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Karen Kar Lye Yee, </li><li class="list-inline-item cited-by__entry__author">Junichi Kumamoto, </li><li class="list-inline-item cited-by__entry__author">Daijiro Inomata, </li><li class="list-inline-item cited-by__entry__author">Naoki Suzuki, </li><li class="list-inline-item cited-by__entry__author">Ryuhei Harada, </li><li class="list-inline-item cited-by__entry__author">Norihiro Yumoto, </li></ul><span class="cited-by__entry__title">Harnessing synaptic vesicle release and recycling with antibody shuttle for targeted delivery of therapeutics to neurons, </span><span class="cited-by__entry__series-title">Molecular Therapy Methods &amp; Clinical Development, </span><span class="cited-by__entry__volume"><strong>33</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(101476), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.omtm.2025.101476" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.omtm.2025.101476</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.omtm.2025.101476" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yongliang Cao, </li><li class="list-inline-item cited-by__entry__author">Yifei Xu, </li><li class="list-inline-item cited-by__entry__author">Meiqun Cao, </li><li class="list-inline-item cited-by__entry__author">Nan Chen, </li><li class="list-inline-item cited-by__entry__author">Qingling Zeng, </li><li class="list-inline-item cited-by__entry__author">Mitchell K.P. Lai, </li><li class="list-inline-item cited-by__entry__author">Dahua Fan, </li><li class="list-inline-item cited-by__entry__author">Gautam Sethi, </li><li class="list-inline-item cited-by__entry__author">Yongkai Cao, </li></ul><span class="cited-by__entry__title">Fluid-based biomarkers for neurodegenerative diseases, </span><span class="cited-by__entry__series-title">Ageing Research Reviews, </span><span class="cited-by__entry__volume"><strong>108</strong>, </span><span class="cited-by__entry__page-range">(102739), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.arr.2025.102739" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.arr.2025.102739</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.arr.2025.102739" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Naoki Suzuki, </li><li class="list-inline-item cited-by__entry__author">Ayumi Nishiyama, </li><li class="list-inline-item cited-by__entry__author">Satoru Ebihara, </li><li class="list-inline-item cited-by__entry__author">Masashi Aoki, </li></ul><span class="cited-by__entry__title">Jacifusen for FUS-ALS: molecular effects and clinical outcomes in a case series, </span><span class="cited-by__entry__series-title">The Lancet, </span><span class="cited-by__entry__volume"><strong>405</strong>, </span><span class="cited-by__entry__issue">10494, </span><span class="cited-by__entry__page-range">(2028-2030), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/S0140-6736(25)01038-4" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/S0140-6736(25)01038-4</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/S0140-6736(25)01038-4" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yu’e Liu, </li><li class="list-inline-item cited-by__entry__author">Guangzhen Wu, </li><li class="list-inline-item cited-by__entry__author">Linjing Feng, </li><li class="list-inline-item cited-by__entry__author">Jialing Li, </li><li class="list-inline-item cited-by__entry__author">Yuyang Xia, </li><li class="list-inline-item cited-by__entry__author">Wenjia Guo, </li><li class="list-inline-item cited-by__entry__author">Kaijun Zhao, </li></ul><span class="cited-by__entry__title">Harnessing Antioxidants in Cancer Therapy: Opportunities, Challenges, and Future Directions, </span><span class="cited-by__entry__series-title">Antioxidants, </span><span class="cited-by__entry__volume"><strong>14</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(674), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/antiox14060674" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/antiox14060674</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/antiox14060674" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-12%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2204705%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2204705" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2204705" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2204705.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204705_f0.jpg"><img src="/cms/10.1056/NEJMoa2204705/asset/2e979330-0135-497d-9176-2e81e9ab8249/assets/images/large/nejmoa2204705_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204705_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204705_f1.jpg"><img src="/cms/10.1056/NEJMoa2204705/asset/c78fcb78-95c7-40a8-a925-d1a698faec93/assets/images/large/nejmoa2204705_f1.jpg" height="3437" width="2231" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Total Superoxidase Dismutase 1 (SOD1) Concentrations in Cerebrospinal Fluid (CSF) and Concentrations of Neurofilament Light Chains (NfL) in Plasma.</div><div class="notes"><div role="doc-footnote">Shown is the course of all randomly assigned participants (intention-to-treat population) over a period of 52 weeks, including those with faster-progressing disease and those with slower-progressing disease. After completing the 28-week placebo-controlled period, all the participants had the opportunity to receive tofersen in the open-label extension. Participants who initiated tofersen at week 0 in the VALOR component of the trial make up the “early-start cohort,” and those who received placebo in VALOR and had the opportunity to cross over to tofersen in the open-label extension are referred to as the “delayed-start cohort.” Participant disposition is summarized in Figure S3 in the <a href="#ap2">Supplementary Appendix</a>. 𝙸 bars represent 95% confidence intervals.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204705_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204705_f2.jpg"><img src="/cms/10.1056/NEJMoa2204705/asset/32ba9148-545e-4d73-be9c-547bc4459e1d/assets/images/large/nejmoa2204705_f2.jpg" height="3438" width="1502" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Analyses of Clinical Function and Survival.</div><div class="notes"><div role="doc-footnote">Shown is the course of all randomly assigned participants (intention-to-treat population). Panels A, B, and C reflect data over a period of 52 weeks since VALOR baseline. Panel D reflects all available follow-up data from VALOR baseline to the data-cutoff date of the open-label extension (January 16, 2022). After completing the 28-week placebo-controlled period, all the participants had the opportunity to receive tofersen in the open-label extension. Participants who initiated tofersen at week 0 in the VALOR component of the trial make up the “early-start cohort,” and those who received placebo in VALOR and had the opportunity to cross over to tofersen in the open-label extension are referred to as the “delayed-start cohort.” Participant disposition is summarized in Figure S3. Numerical results at 52 weeks were not adjusted for multiple comparisons. Total scores on the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R) (Panel A) range from 0 to 48, with higher scores indicating better function. The handheld dynamometry megascore (Panel C) is the average of z-scores across 16 muscle groups in the arms and legs, with higher values indicating greater strength. 𝙸 bars represent standard errors.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204705_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204705_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2204705/asset/b689ed23-3805-4fe6-8e60-c86f5bac03a0/assets/images/large/nejmoa2204705_t1.jpg" height="2089" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="2"><span>Faster-Progression Subgroup (N=60)<a href="#core-t1fn2" role="doc-noteref">†</a></span></th><th class="txxx-borders" colspan="2"><span>Slower-Progression Subgroup (N=48)</span></th><th class="txxr-borders" colspan="2"><span>Overall (N=108)<a href="#core-t1fn3" role="doc-noteref">‡</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Placebo<br>(N=21)</th><th class="xxxx-borders">Tofersen<br>(N=39)</th><th class="xxxx-borders">Placebo<br>(N=15)</th><th class="xxxx-borders">Tofersen<br>(N=33)</th><th class="xxxx-borders">Placebo<br>(N=36)</th><th class="xxxr-borders">Tofersen<br>(N=72)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">54.0±12.2</td><td class="xxxx-borders shading">47.3±14.3</td><td class="xxxx-borders shading">47.3±9.8</td><td class="xxxx-borders shading">49.0±10.5</td><td class="xxxx-borders shading">51.2±11.6</td><td class="xxxr-borders shading">48.1±12.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders">11 (52)</td><td class="xxxx-borders">22 (56)</td><td class="xxxx-borders">8 (53)</td><td class="xxxx-borders">21 (64)</td><td class="xxxx-borders">19 (53)</td><td class="xxxr-borders">43 (60)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Body-mass index<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">28.0±6.2</td><td class="xxxx-borders shading">26.7±6.4</td><td class="xxxx-borders shading">26.6±7.0</td><td class="xxxx-borders shading">26.2±4.6</td><td class="xxxx-borders shading">27.4±6.5</td><td class="xxxr-borders shading">26.4±5.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Riluzole use — no. (%)</td><td class="xxxx-borders">13 (62)</td><td class="xxxx-borders">25 (64)</td><td class="xxxx-borders">9 (60)</td><td class="xxxx-borders">20 (61)</td><td class="xxxx-borders">22 (61)</td><td class="xxxr-borders">45 (62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Edaravone use — no. (%)</td><td class="xxxx-borders shading">1 (5)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">2 (13)</td><td class="xxxx-borders shading">4 (12)</td><td class="xxxx-borders shading">3 (8)</td><td class="xxxr-borders shading">6 (8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Time from symptom onset — min<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median (IQR)</td><td class="xxxx-borders shading">8.3 (5.1 to 12.1)</td><td class="xxxx-borders shading">8.3 (6.0 to 10.4)</td><td class="xxxx-borders shading">39.6 (30.3 to 53.6)</td><td class="xxxx-borders shading">35.5 (19.5 to 60.9)</td><td class="xxxx-borders shading">14.6 (6.6 to 32.0)</td><td class="xxxr-borders shading">11.4 (7.2 to 28.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Range</td><td class="xxxx-borders">2.4 to 21.3</td><td class="xxxx-borders">1.7 to 18.5</td><td class="xxxx-borders">11.8 to 103.2</td><td class="xxxx-borders">3.9 to 145.7</td><td class="xxxx-borders">2.4 to 103.2</td><td class="xxxr-borders">1.7 to 145.7</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Concentration of neurofilament light chains in plasma — pg/ml</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean</td><td class="xxxx-borders">127.3±94.4</td><td class="xxxx-borders">146.2±82.6</td><td class="xxxx-borders">37.0±29.5</td><td class="xxxx-borders">47.6±41.8</td><td class="xxxx-borders">89.7±86.5</td><td class="xxxr-borders">100.4±82.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Geometric mean</td><td class="xxxx-borders shading">92.7</td><td class="xxxx-borders shading">121.8</td><td class="xxxx-borders shading">28.4</td><td class="xxxx-borders shading">33.2</td><td class="xxxx-borders shading">56.6</td><td class="xxxr-borders shading">66.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Range</td><td class="xxxx-borders">9 to 370</td><td class="xxxx-borders">12 to 329</td><td class="xxxx-borders">8 to 99</td><td class="xxxx-borders">5 to 211</td><td class="xxxx-borders">8 to 370</td><td class="xxxr-borders">5 to 329</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ALSFRS-R prerandomization slope — points per mo<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean</td><td class="xxxx-borders">–1.81±1.17</td><td class="xxxx-borders">–1.74±1.58</td><td class="xxxx-borders">–0.26±0.25</td><td class="xxxx-borders">–0.30±0.20</td><td class="xxxx-borders">–1.16±1.19</td><td class="xxxr-borders">–1.08±1.37</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">–4.91 to –0.42</td><td class="xxxx-borders shading">–8.30 to –0.39</td><td class="xxxx-borders shading">–0.84 to –0.02</td><td class="xxxx-borders shading">–0.77 to 0.00</td><td class="xxxx-borders shading">–4.91 to –0.02</td><td class="xxxr-borders shading">–8.30 to 0.00</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">ALSFRS-R run-in slope — points per mo<a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean</td><td class="xxxx-borders shading">–1.3±3.9</td><td class="xxxx-borders shading">–1.8±2.5</td><td class="xxxx-borders shading">0.1±1.9</td><td class="xxxx-borders shading">–0.1±1.3</td><td class="xxxx-borders shading">–0.7±3.3</td><td class="xxxr-borders shading">–1.0±2.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Range</td><td class="xxxx-borders">–11 to 10</td><td class="xxxx-borders">–9 to 3</td><td class="xxxx-borders">–3 to 4</td><td class="xxxx-borders">–3 to 4</td><td class="xxxx-borders">–11 to 10</td><td class="xxxr-borders">–9 to 4</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ALSFRS-R total score</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean</td><td class="xxxx-borders">35.4±5.7</td><td class="xxxx-borders">36.0±6.4</td><td class="xxxx-borders">39.9±5.1</td><td class="xxxx-borders">38.1±5.1</td><td class="xxxx-borders">37.3±5.8</td><td class="xxxr-borders">36.9±5.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">24 to 45</td><td class="xxxx-borders shading">15 to 44</td><td class="xxxx-borders shading">32 to 47</td><td class="xxxx-borders shading">26 to 48</td><td class="xxxx-borders shading">24 to 47</td><td class="xxxr-borders shading">15 to 48</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Percentage of predicted slow vital capacity</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean</td><td class="xxxx-borders shading">83.7±17.9</td><td class="xxxx-borders shading">80.3±14.2</td><td class="xxxx-borders shading">87.1±14.8</td><td class="xxxx-borders shading">84.2±19.0</td><td class="xxxx-borders shading">85.1±16.5</td><td class="xxxr-borders shading">82.1±16.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Range</td><td class="xbxx-borders">57.4 to 120.4</td><td class="xbxx-borders">46.7 to 114.8</td><td class="xbxx-borders">54.8 to 114.4</td><td class="xbxx-borders">55.4 to 134.7</td><td class="xbxx-borders">54.8 to 120.4</td><td class="xbxr-borders">46.7 to 134.7</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. Total scores on the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R) range from 0 to 48, with higher scores indicating better function. IQR denotes interquartile range.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">These participants were included in the randomized VALOR component of the trial.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">These participants were included in the combined analysis.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">The time since the onset of symptoms of amyotrophic lateral sclerosis (ALS) was calculated in months as (date of baseline minus date of ALS symptom onset) divided by 30.4375.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">The prerandomization ALSFRS-R slope was calculated as (maximum possible score of 48 minus ALSFRS-R score at baseline [day 1]) divided by time since symptom onset.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">The run-in ALSFRS-R slope reflects the rate of decline in the ALSFRS-R score from screening to day 15 (run-in period of approximately 42 days).</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Participants at Baseline (Intention-to-Treat Population).<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204705_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204705_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2204705/asset/da490f89-2198-4f02-862c-445600baa7f5/assets/images/large/nejmoa2204705_t2.jpg" height="1865" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">Placebo<br>(N=21)</th><th class="txxr-borders">Tofersen<br>(N=39)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Primary end point</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">ALSFRS-R total score<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Adjusted mean change from VALOR baseline</td><td class="xxxx-borders shading">–8.14</td><td class="xxxr-borders shading">–6.98</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Adjusted mean difference: tofersen minus placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">1.2 (–3.2 to 5.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">P value according to joint rank test and multiple imputation</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">0.97</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Secondary end points</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Total SOD1 concentration in CSF</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjusted geometric mean ratio to VALOR baseline</td><td class="xxxx-borders">1.16</td><td class="xxxr-borders">0.71</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Geometric mean ratio: tofersen vs. placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">0.62 (0.49 to 0.78)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Concentration of neurofilament light chains in plasma</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Adjusted geometric mean ratio to VALOR baseline</td><td class="xxxx-borders shading">1.20</td><td class="xxxr-borders shading">0.40</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Geometric mean ratio: tofersen vs. placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">0.33 (0.25 to 0.45)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Percentage of predicted slow vital capacity — percentage points</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjusted mean change from VALOR baseline</td><td class="xxxx-borders">–22.20</td><td class="xxxr-borders">–14.31</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Adjusted mean difference: tofersen minus placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">7.9 (−3.5 to 19.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Handheld dynamometry megascore</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Adjusted mean change from VALOR baseline</td><td class="xxxx-borders shading">–0.37</td><td class="xxxr-borders shading">–0.34</td></tr><tr data-type="row"><td class="xxlx-borders hanging12">Adjusted mean difference: tofersen minus placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">0.02 (–0.21 to 0.26)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Death or permanent ventilation</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of events/total no. of participants (%)</td><td class="xxxx-borders">2/21 (10)</td><td class="xxxr-borders">4/39 (10)</td></tr><tr data-type="row"><td class="xxlx-borders hanging12 shading">Hazard ratio (95% CI)<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">1.39 (0.22 to 8.80)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Death</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of events/total no. of participants (%)</td><td class="xxxx-borders shading">0/21</td><td class="xxxr-borders shading">1/39 (3)</td></tr><tr data-type="row"><td class="xblx-borders hanging12">Hazard ratio (95% CI)<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xbxx-borders">&nbsp;</td><td class="xbxr-borders" data-xml-align="center">NE (NE to NE)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Shown are the results at the end of the placebo-controlled period (week 28). CSF denotes cerebrospinal fluid, NE could not be estimated, and SOD1 superoxide dismutase 1.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Sequential analysis failed at this point, and all subsequent secondary end points are considered to be not significantly different between trial groups.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">The hazard ratio is based on a Cox proportional-hazards model adjusted for baseline disease duration since symptom onset, baseline ALSFRS-R score, and use of riluzole or edaravone.</div></div></div></figcaption></a><figcaption><div class="caption">Primary and Secondary End Points in VALOR in the Faster-Progression Subgroup.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204705_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204705_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2204705/asset/b5e5107f-e3cd-4ebd-ade8-3995088860e7/assets/images/large/nejmoa2204705_t3.jpg" height="2434" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Adverse Event</th><th class="txxx-borders" colspan="2"><span>VALOR</span></th><th class="txxr-borders">VALOR and Open-Label Extension Combined<a href="#core-t3fn2" role="doc-noteref">†</a></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Placebo<br>(N=36)</th><th class="xxxx-borders">Tofersen<br>(N=72)<a href="#core-t3fn2" role="doc-noteref">†</a></th><th class="xxxr-borders">Tofersen<br>(N=104)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="3"><span>number of participants (percent)<a href="#core-t3fn3" role="doc-noteref">‡</a></span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any event</td><td class="xxxx-borders shading">34 (94)</td><td class="xxxx-borders shading">69 (96)</td><td class="xxxr-borders shading">102 (98)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Event related to trial agent<a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">28 (39)</td><td class="xxxr-borders">63 (61)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Event related to lumbar puncture<a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">29 (81)</td><td class="xxxx-borders shading">58 (81)</td><td class="xxxr-borders shading">84 (81)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serious event</td><td class="xxxx-borders">5 (14)</td><td class="xxxx-borders">13 (18)</td><td class="xxxr-borders">38 (37)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious event related to trial agent<a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">4 (6)</td><td class="xxxr-borders shading">7 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Event with fatal outcome</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">14 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Events leading to discontinuation of trial agent</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">4 (6)</td><td class="xxxr-borders shading">18 (17)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Adverse events occurring in ≥15% of participants in combined analysis<a href="#core-t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Headache</td><td class="xxxx-borders shading">16 (44)</td><td class="xxxx-borders shading">33 (46)</td><td class="xxxr-borders shading">58 (56)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Procedural pain</td><td class="xxxx-borders">21 (58)</td><td class="xxxx-borders">41 (57)</td><td class="xxxr-borders">56 (54)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Fall</td><td class="xxxx-borders shading">15 (42)</td><td class="xxxx-borders shading">17 (24)</td><td class="xxxr-borders shading">40 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Back pain</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">15 (21)</td><td class="xxxr-borders">39 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pain in arm or leg</td><td class="xxxx-borders shading">6 (17)</td><td class="xxxx-borders shading">19 (26)</td><td class="xxxr-borders shading">38 (37)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Arthralgia</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">10 (14)</td><td class="xxxr-borders">28 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">CSF protein concentration increased</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">6 (8)</td><td class="xxxr-borders shading">24 (23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Fatigue</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">12 (17)</td><td class="xxxr-borders">24 (23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Post–lumbar puncture syndrome</td><td class="xxxx-borders shading">11 (31)</td><td class="xxxx-borders shading">13 (18)</td><td class="xxxr-borders shading">22 (21)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Myalgia</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">10 (14)</td><td class="xxxr-borders">21 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">CSF white-cell count increased</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">7 (10)</td><td class="xxxr-borders shading">19 (18)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nausea</td><td class="xxxx-borders">6 (17)</td><td class="xxxx-borders">9 (12)</td><td class="xxxr-borders">17 (16)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">4 (11)</td><td class="xxxx-borders shading">6 (8)</td><td class="xxxr-borders shading">17 (16)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Pyrexia</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">3 (4)</td><td class="xxxr-borders">16 (15)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Serious adverse events occurring in ≥2% of participants in combined analysis<a href="#core-t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Respiratory failure</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">10 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pneumonia aspiration</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (3)</td><td class="xxxr-borders shading">9 (9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Pulmonary embolism</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">3 (4)</td><td class="xxxr-borders">4 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Acute respiratory failure</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">4 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Dysphagia</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxr-borders">3 (3)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Shown are events that had an onset date on or after the start of the trial agent or that worsened after the start of the trial agent.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">An event in a participant who received placebo during VALOR is counted only once. An event in a participant who received tofersen during VALOR is counted in both columns for tofersen.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">A participant could appear in more than one category.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">The relatedness of an event to the trial agent or lumbar puncture was assessed by the investigator.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t3fn5" role="paragraph" data-to-manipulate="true">A participant is counted only once for each preferred term (<i>Medical Dictionary for Regulatory Activities</i>, version 24.0).</div></div></div></figcaption></a><figcaption><div class="caption">Summary of Adverse Events.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2204705_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2204705</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Bunton-Stasyshyn RK, Saccon RA, Fratta P, Fisher EM. SOD1 function and its implications for amyotrophic lateral sclerosis pathology: new and renascent themes. <em>Neuroscientist</em> 2015;21:519-529.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/1073858414561795" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25492944/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000362290000011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SOD1+function+and+its+implications+for+amyotrophic+lateral+sclerosis+pathology%3A+new+and+renascent+themes.&amp;publication_year=2015&amp;journal=Neuroscientist&amp;pages=519-529&amp;doi=10.1177%2F1073858414561795&amp;pmid=25492944" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] SOD1). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of function of the mutant SOD1 protein. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Müller K, Brenner D, Weydt P, et al. Comprehensive analysis of the mutation spectrum in 301 German ALS families. <em>J Neurol Neurosurg Psychiatry</em> 2018;89:817-827.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/jnnp-2017-317611" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29650794/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000442475000013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comprehensive+analysis+of+the+mutation+spectrum+in+301+German+ALS+families.&amp;publication_year=2018&amp;journal=J+Neurol+Neurosurg+Psychiatry&amp;pages=817-827&amp;doi=10.1136%2Fjnnp-2017-317611&amp;pmid=29650794" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Huai J, Zhang Z. Structural properties and interaction partners of familial ALS-associated SOD1 mutants. <em>Front Neurol</em> 2019;10:527-527.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3389/fneur.2019.00527" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31164862/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000468416400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Structural+properties+and+interaction+partners+of+familial+ALS-associated+SOD1+mutants.&amp;publication_year=2019&amp;journal=Front+Neurol&amp;pages=527-527&amp;doi=10.3389%2Ffneur.2019.00527&amp;pmid=31164862" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Bali T, Self W, Liu J, et al. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. <em>J Neurol Neurosurg Psychiatry</em> 2017;88:99-105.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/jnnp-2016-313521" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27261500/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393903700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Defining+SOD1+ALS+natural+history+to+guide+therapeutic+clinical+trial+design.&amp;publication_year=2017&amp;journal=J+Neurol+Neurosurg+Psychiatry&amp;pages=99-105&amp;doi=10.1136%2Fjnnp-2016-313521&amp;pmid=27261500" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Amyotrophic Lateral Sclerosis online Database. SOD1 gene summary (<a href="https://alsod.ac.uk/output/gene.php/SOD1">https://alsod.ac.uk/output/gene.php/SOD1</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SOD1+gene+summary" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Hayashi Y, Homma K, Ichijo H. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS. <em>Adv Biol Regul</em> 2016;60:95-104.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jbior.2015.10.006" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26563614/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SOD1+in+neurotoxicity+and+its+controversial+roles+in+SOD1+mutation-negative+ALS.&amp;publication_year=2016&amp;journal=Adv+Biol+Regul&amp;pages=95-104&amp;doi=10.1016%2Fj.jbior.2015.10.006&amp;pmid=26563614" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Coppedè F, Stoccoro A, Mosca L, et al. Increase in DNA methylation in patients with amyotrophic lateral sclerosis carriers of not fully penetrant SOD1 mutations. <em>Amyotroph Lateral Scler Frontotemporal Degener</em> 2018;19:93-101.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/21678421.2017.1367401" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28859526/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000425671500014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Increase+in+DNA+methylation+in+patients+with+amyotrophic+lateral+sclerosis+carriers+of+not+fully+penetrant+SOD1+mutations.&amp;publication_year=2018&amp;journal=Amyotroph+Lateral+Scler+Frontotemporal+Degener&amp;pages=93-101&amp;doi=10.1080%2F21678421.2017.1367401&amp;pmid=28859526" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Ekhtiari Bidhendi E, Bergh J, Zetterström P, et al. Mutant superoxide dismutase aggregates from human spinal cord transmit amyotrophic lateral sclerosis. <em>Acta Neuropathol</em> 2018;136:939-953.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00401-018-1915-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30284034/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000451952700008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mutant+superoxide+dismutase+aggregates+from+human+spinal+cord+transmit+amyotrophic+lateral+sclerosis.&amp;publication_year=2018&amp;journal=Acta+Neuropathol&amp;pages=939-953&amp;doi=10.1007%2Fs00401-018-1915-y&amp;pmid=30284034" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. <em>J Cell Biol</em> 2009;187:761-772.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1083/jcb.200908164" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19951898/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000272702500004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Non-cell+autonomous+toxicity+in+neurodegenerative+disorders%3A+ALS+and+beyond.&amp;publication_year=2009&amp;journal=J+Cell+Biol&amp;pages=761-772&amp;doi=10.1083%2Fjcb.200908164&amp;pmid=19951898" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">McCampbell A, Cole T, Wegener AJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. <em>J Clin Invest</em> 2018;128:3558-3567.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI99081" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30010620/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000440461500036" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antisense+oligonucleotides+extend+survival+and+reverse+decrement+in+muscle+response+in+ALS+models.&amp;publication_year=2018&amp;journal=J+Clin+Invest&amp;pages=3558-3567&amp;doi=10.1172%2FJCI99081&amp;pmid=30010620" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of function of the mutant SOD1 protein. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] messenger RNA. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Saccon RA, Bunton-Stasyshyn RK, Fisher EM, Fratta P. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? <em>Brain</em> 2013;136:2342-2358.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/brain/awt097" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23687121/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000322338000009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Is+SOD1+loss+of+function+involved+in+amyotrophic+lateral+sclerosis%3F&amp;publication_year=2013&amp;journal=Brain&amp;pages=2342-2358&amp;doi=10.1093%2Fbrain%2Fawt097&amp;pmid=23687121" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Sau D, De Biasi S, Vitellaro-Zuccarello L, et al. Mutation of SOD1 in ALS: a gain of a loss of function. <em>Hum Mol Genet</em> 2007;16:1604-1618.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/hmg/ddm110" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17504823/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000248447200009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mutation+of+SOD1+in+ALS%3A+a+gain+of+a+loss+of+function.&amp;publication_year=2007&amp;journal=Hum+Mol+Genet&amp;pages=1604-1618&amp;doi=10.1093%2Fhmg%2Fddm110&amp;pmid=17504823" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. <em>Nat Rev Neurol</em> 2018;14:9-21.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrneurol.2017.148" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29192260/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423052600009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antisense+oligonucleotides%3A+the+next+frontier+for+treatment+of+neurological+disorders.&amp;publication_year=2018&amp;journal=Nat+Rev+Neurol&amp;pages=9-21&amp;doi=10.1038%2Fnrneurol.2017.148&amp;pmid=29192260" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. <em>J Clin Invest</em> 2006;116:2290-2296.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI25424" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16878173/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000239499300031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antisense+oligonucleotide+therapy+for+neurodegenerative+disease.&amp;publication_year=2006&amp;journal=J+Clin+Invest&amp;pages=2290-2296&amp;doi=10.1172%2FJCI25424&amp;pmid=16878173" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1–2 trial of antisense oligonucleotide tofersen for <i>SOD1</i> ALS. <em>N Engl J Med</em> 2020;383:109-119.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_16_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2204705&amp;key=10.1056%2FNEJMoa2003715&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32640130/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000571894800010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+1%E2%80%932+trial+of+antisense+oligonucleotide+tofersen+for+SOD1+ALS.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=109-119&amp;doi=10.1056%2FNEJMoa2003715&amp;pmid=32640130" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] messenger RNA. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the full text of this article at NEJM.org). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] phase 1–2 multiple-ascending-dose study </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Abu-Rumeileh S, Vacchiano V, Zenesini C, et al. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. <em>J Neurol</em> 2020;267:1699-1708.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00415-020-09761-z" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32100123/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000515910200003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnostic-prognostic+value+and+electrophysiological+correlates+of+CSF+biomarkers+of+neurodegeneration+and+neuroinflammation+in+amyotrophic+lateral+sclerosis.&amp;publication_year=2020&amp;journal=J+Neurol&amp;pages=1699-1708&amp;doi=10.1007%2Fs00415-020-09761-z&amp;pmid=32100123" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] from March 2019 through July 2021. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] a prognostic marker of disease progression, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. <em>Neurology</em> 2020;95(1):e59-e69.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0000000000009559" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32385188/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000559750000015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Validation+of+serum+neurofilaments+as+prognostic+and+potential+pharmacodynamic+biomarkers+for+ALS.&amp;publication_year=2020&amp;journal=Neurology&amp;pages=e59-e69&amp;doi=10.1212%2FWNL.0000000000009559&amp;pmid=32385188" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">De Schaepdryver M, Lunetta C, Tarlarini C, et al. Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis. <em>J Neurol Neurosurg Psychiatry</em> 2020;91:436-437.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/jnnp-2019-322309" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32029541/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000523679000017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Neurofilament+light+chain+and+C+reactive+protein+explored+as+predictors+of+survival+in+amyotrophic+lateral+sclerosis.&amp;publication_year=2020&amp;journal=J+Neurol+Neurosurg+Psychiatry&amp;pages=436-437&amp;doi=10.1136%2Fjnnp-2019-322309&amp;pmid=32029541" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Gaiani A, Martinelli I, Bello L, et al. Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. <em>JAMA Neurol</em> 2017;74:525-532.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamaneurol.2016.5398" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28264096/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400838900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnostic+and+prognostic+biomarkers+in+amyotrophic+lateral+sclerosis%3A+neurofilament+light+chain+levels+in+definite+subtypes+of+disease.&amp;publication_year=2017&amp;journal=JAMA+Neurol&amp;pages=525-532&amp;doi=10.1001%2Fjamaneurol.2016.5398&amp;pmid=28264096" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. <em>Neurology</em> 2015;84:2247-2257.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0000000000001642" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25934855/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000360568500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Neurofilament+light+chain%3A+a+prognostic+biomarker+in+amyotrophic+lateral+sclerosis.&amp;publication_year=2015&amp;journal=Neurology&amp;pages=2247-2257&amp;doi=10.1212%2FWNL.0000000000001642&amp;pmid=25934855" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. <em>Front Neurol</em> 2019;9:1167-1167.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3389/fneur.2018.01167" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30713520/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000455992900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnostic+and+prognostic+performance+of+neurofilaments+in+ALS.&amp;publication_year=2019&amp;journal=Front+Neurol&amp;pages=1167-1167&amp;doi=10.3389%2Ffneur.2018.01167&amp;pmid=30713520" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. <em>J Neurol Neurosurg Psychiatry</em> 2016;87:12-20.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26296871/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000366732700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Neurofilaments+in+the+diagnosis+of+motoneuron+diseases%3A+a+prospective+study+on+455+patients.&amp;publication_year=2016&amp;journal=J+Neurol+Neurosurg+Psychiatry&amp;pages=12-20&amp;pmid=26296871" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Thompson AG, Gray E, Verber N, et al. Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. <em>Brain Commun</em> 2022;4:fcac029-fcac029.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/braincomms/fcac029" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35224491/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Multicentre+appraisal+of+amyotrophic+lateral+sclerosis+biofluid+biomarkers+shows+primacy+of+blood+neurofilament+light+chain.&amp;publication_year=2022&amp;journal=Brain+Commun&amp;pages=fcac029-fcac029&amp;doi=10.1093%2Fbraincomms%2Ffcac029&amp;pmid=35224491" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. <em>J Neurol Neurosurg Psychiatry</em> 2019;90:157-164.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/jnnp-2018-318704" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30309882/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000471112000009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Neurofilament+light+chain+in+serum+for+the+diagnosis+of+amyotrophic+lateral+sclerosis.&amp;publication_year=2019&amp;journal=J+Neurol+Neurosurg+Psychiatry&amp;pages=157-164&amp;doi=10.1136%2Fjnnp-2018-318704&amp;pmid=30309882" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Benatar M, Wuu J, Andersen PM, et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive <i>SOD1</i> ALS. <em>Neurology</em> 2018;90(7):e565-e574.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0000000000004960" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29367439/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000427813200004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized%2C+double-blind%2C+placebo-controlled+trial+of+arimoclomol+in+rapidly+progressive+SOD1+ALS.&amp;publication_year=2018&amp;journal=Neurology&amp;pages=e565-e574&amp;doi=10.1212%2FWNL.0000000000004960&amp;pmid=29367439" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Ludolph AC, Dorst J, Dreyhaupt J, et al. Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. <em>Ann Neurol</em> 2020;87:206-216.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ana.25661" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31849093/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505602400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+high-caloric+nutrition+on+survival+in+amyotrophic+lateral+sclerosis.&amp;publication_year=2020&amp;journal=Ann+Neurol&amp;pages=206-216&amp;doi=10.1002%2Fana.25661&amp;pmid=31849093" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Ludolph AC, Schuster J, Dorst J, et al. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. <em>Lancet Neurol</em> 2018;17:681-688.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(18)30176-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29934198/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000439057500012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+rasagiline+as+an+add-on+therapy+to+riluzole+in+patients+with+amyotrophic+lateral+sclerosis%3A+a+randomised%2C+double-blind%2C+parallel-group%2C+placebo-controlled%2C+phase+2+trial.&amp;publication_year=2018&amp;journal=Lancet+Neurol&amp;pages=681-688&amp;doi=10.1016%2FS1474-4422%2818%2930176-5&amp;pmid=29934198" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Benatar M, Wuu J, Andersen PM, et al. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. <em>Neurotherapeutics</em> 2022 May 18 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s13311-022-01237-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35585374/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000797294200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Design+of+a+randomized%2C+placebo-controlled%2C+phase+3+trial+of+tofersen+initiated+in+clinically+presymptomatic+SOD1+variant+carriers%3A+the+ATLAS+study.&amp;publication_year=2022&amp;journal=Neurotherapeutics&amp;doi=10.1007%2Fs13311-022-01237-4&amp;pmid=35585374" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Concord, Massachusetts</span></div><div><span>Ophthalmology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883738/ophthalmologist-generalist/?query=fjwp&amp;rid=980">Ophthalmologist - Generalist</a></div></div><div class="nejm-widget_item"><div><span> New York City, New York</span></div><div><span>Surgery, Cardiovascular / Thoracic</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/703423/advanced-coronary-and-minimally-invasive-robotic-cardiac-surgery-fellowship-lenox-hill-hospital/?query=fjwp&amp;rid=3059">Advanced Coronary and Minimally Invasive Robotic Cardiac Surgery Fellowship - Lenox Hill Hospital</a></div></div><div class="nejm-widget_item"><div><span> Lock Haven, Pennsylvania</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/879132/family-medicine-physician-outpatient-only/?query=fjwf&amp;rid=764">Family Medicine Physician Outpatient Only</a></div></div><div class="nejm-widget_item"><div><span> Sayre, Pennsylvania</span></div><div><span>Urology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/879513/urologist/?query=fjwf&amp;rid=899">Urologist</a></div></div><div class="nejm-widget_item"><div><span> Modesto, California</span></div><div><span>Psychiatry</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889309/physician-psychiatry-modesto-ca-/?query=fjwf&amp;rid=845677">Physician, Psychiatry (Modesto, CA)</a></div></div><div class="nejm-widget_item"><div><span> Kyle, Texas</span></div><div><span>Primary Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/880947/primary-care-physician-fp-im-wellmed-medical-group-kyle-tx/?query=fjwf&amp;rid=220874">Primary Care Physician - FP/IM - WellMed Medical Group - Kyle, TX</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2204705&amp;pubId=41284273&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6eb9ff0710176-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6eb9ff0710176-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6eb9ff0710176-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$246072933$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$246072933$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$246072933$--></div></div><div class="mlt-body"><!--?lit$246072933$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$246072933$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$246072933$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$246072933$-->Jul 09, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2003715?query=recirc_Semantic" target="_self">Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <em>SOD1</em> ALS</a></div><div class="mlt-article-authors"><!--?lit$246072933$-->T. Miller and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$246072933$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$246072933$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$246072933$-->Aug 15, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2314598?query=recirc_Semantic" target="_self">Brief Report: Longevity of a Brain–Computer Interface for Amyotrophic Lateral Sclerosis</a></div><div class="mlt-article-authors"><!--?lit$246072933$-->M.J. Vansteensel and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$246072933$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$246072933$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$246072933$-->Sep 03, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1916945?query=recirc_Semantic" target="_self">Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis</a></div><div class="mlt-article-authors"><!--?lit$246072933$-->S. Paganoni and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$246072933$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$246072933$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$246072933$-->Jan 09, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2408941?query=recirc_Semantic" target="_self">Clearance of Driver Mutations after Transplantation for Myelofibrosis</a></div><div class="mlt-article-authors"><!--?lit$246072933$-->N. Gagelmann and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$246072933$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$246072933$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$246072933$-->Jul 25, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2309160?query=recirc_Semantic" target="_self">Brief Report: Sotorasib for Vascular Malformations Associated with <em>KRAS</em> G12C Mutation</a></div><div class="mlt-article-authors"><!--?lit$246072933$-->A. Fraissenon and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2204705?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2204705" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2204705.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2204705"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2206286" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMra2025746" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Burkitt’s Lymphoma</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204705_f0.jpg"><img src="/cms/10.1056/NEJMoa2204705/asset/2e979330-0135-497d-9176-2e81e9ab8249/assets/images/large/nejmoa2204705_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204705_f1.jpg"><img src="/cms/10.1056/NEJMoa2204705/asset/c78fcb78-95c7-40a8-a925-d1a698faec93/assets/images/large/nejmoa2204705_f1.jpg" height="3437" width="2231" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Total Superoxidase Dismutase 1 (SOD1) Concentrations in Cerebrospinal Fluid (CSF) and Concentrations of Neurofilament Light Chains (NfL) in Plasma.</div><div class="notes"><div role="doc-footnote">Shown is the course of all randomly assigned participants (intention-to-treat population) over a period of 52 weeks, including those with faster-progressing disease and those with slower-progressing disease. After completing the 28-week placebo-controlled period, all the participants had the opportunity to receive tofersen in the open-label extension. Participants who initiated tofersen at week 0 in the VALOR component of the trial make up the “early-start cohort,” and those who received placebo in VALOR and had the opportunity to cross over to tofersen in the open-label extension are referred to as the “delayed-start cohort.” Participant disposition is summarized in Figure S3 in the <a href="#ap2">Supplementary Appendix</a>. 𝙸 bars represent 95% confidence intervals.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2204705_f2.jpg"><img src="/cms/10.1056/NEJMoa2204705/asset/32ba9148-545e-4d73-be9c-547bc4459e1d/assets/images/large/nejmoa2204705_f2.jpg" height="3438" width="1502" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Analyses of Clinical Function and Survival.</div><div class="notes"><div role="doc-footnote">Shown is the course of all randomly assigned participants (intention-to-treat population). Panels A, B, and C reflect data over a period of 52 weeks since VALOR baseline. Panel D reflects all available follow-up data from VALOR baseline to the data-cutoff date of the open-label extension (January 16, 2022). After completing the 28-week placebo-controlled period, all the participants had the opportunity to receive tofersen in the open-label extension. Participants who initiated tofersen at week 0 in the VALOR component of the trial make up the “early-start cohort,” and those who received placebo in VALOR and had the opportunity to cross over to tofersen in the open-label extension are referred to as the “delayed-start cohort.” Participant disposition is summarized in Figure S3. Numerical results at 52 weeks were not adjusted for multiple comparisons. Total scores on the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R) (Panel A) range from 0 to 48, with higher scores indicating better function. The handheld dynamometry megascore (Panel C) is the average of z-scores across 16 muscle groups in the arms and legs, with higher values indicating greater strength. 𝙸 bars represent standard errors.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Participants at Baseline (Intention-to-Treat Population).<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Primary and Secondary End Points in VALOR in the Faster-Progression Subgroup.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Summary of Adverse Events.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/387/12" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 387 No. 12</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 22, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2200433" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">The GRADE Study Research Group</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 22, 2022</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2200436" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">The GRADE Study Research Group</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 22, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2206286" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">S.D. Solomon and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2204705%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2204705&amp;pubId=41284273&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2204705%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2204705&amp;pubId=41284273&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id03665089577205788" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6eb9ff0710176-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6eb9ff0710176-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6eb9ff0710176-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6eb9ff0710176-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6eb9ff0710176-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6eb9ff0710176-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6eb9ff0710176-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6eb9ff0710176-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6eb9ff0710176-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6eb9ff0710176-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6eb9fed040176',t:'MTc0OTUzODA3OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6eb9fed040176&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><noi-bklmmrvexdij></noi-bklmmrvexdij><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2204705?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=3-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" data-transactionid="82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" id="captureIFrame_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" target="captureIFrame_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" name="capture_screen"><input id="capture_signIn_js_version_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" name="js_version"><input id="capture_signIn_transactionId_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" data-capturefield="undefined" value="82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" type="hidden" class="capture_transactionId_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" name="capture_transactionId"><input id="capture_signIn_form_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" name="form"><input id="capture_signIn_flow_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" name="flow"><input id="capture_signIn_client_id_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" name="client_id"><input id="capture_signIn_redirect_uri_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" name="redirect_uri"><input id="capture_signIn_response_type_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" name="response_type"><input id="capture_signIn_flow_version_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" name="flow_version"><input id="capture_signIn_settings_version_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" name="settings_version"><input id="capture_signIn_locale_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" name="locale"><input id="capture_signIn_recaptcha_version_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_82oevzf8ma22sdgjm27urjm02tcqkuq1ege8jn12" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>